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Preface 
This thesis is a result of three years of graduate work performed at the Hevesy Laboratory, Center for 
Nuclear Technology, DTU Risø Campus, The Technical University of Denmark, under the supervision of 
Dr. Fedor Zhuravlev, senior scientist at the Hevesy Lab. The work has been funded by a scholarship 
“Mobility” (The Council for Research and innovation, DTU, project number 59510). 
The main parts of the work presented here are Chapter 1 (introduction to PET), Chapter 2 (Co(salen)-
mediated enantioselective radiofluorination of epoxides) and Chapter 3 (synthesis and biological 
evaluation of both enantiomers of [
18
F]FMISO). 
The purpose of the 1
st
 Chapter is to provide background information about PET, PET isotopes and 
18
F-
radiopharmaceuticals in general. 
The background about cold 
19
F fluorination of epoxides and the development of Co(salen)-mediated 
enantioselective radiofluorination of epoxides methodology is presented in the 2
nd
 Chapter and the 
Appendix. 
And the 3
rd
 Chapter provides the overview of [
18
F]FMISO radiosynthesis methods, the development of our 
method, automated radiosynthesis and in vivo studies of both the R and the S enantiomers of 
[
18
F]FMISO. 
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Abstract 
The purpose of this PhD project was to develop an enantioselective cobalt-mediated radiofluorination of 
epoxides and apply this methodology for radiosynthesis of the PET radiopharmaceutical [
18
F]FMISO. The 
developed procedure utilizes [
18
F]HF-gas (as an efficient source of nucleophilic 
18
F-fluoride) in a 
combination with chiral base ((-)tetramisole), chiral Lewis acid ((R,R)-Co(salen)) and 
hexafluoroisopropanol, providing the corresponding (S)-[
18
F]fluorohydrines enantioselectively (20-46% 
enantiomeric excess) with high yields (78-93 % radiochemical yield). The enantioselective Co(salen)-
mediated no-carrier-added radiofluorination of epoxides has been achieved for the first time. A number of 
model meso-epoxides were successfully radiofluorinated producing 
18
F-fluorohidrines in high RCC and 
RCY, and modest enantioselectivity. The developed procedure is simple, rapid and lends itself to easy 
automation. This methodology was adopted for the first automated enantioselective single step 
radiosynthesis of PET hypoxia radiotracer [
18
F]FMISO in 81% RCY and 55% enantioselectivity. The use 
of enantiopure substrates for the synthesis of both enantiomers allowed us to obtain the (S) and (R)-
[
18
F]FMISO enantiomers with > 99% enantiopurity. In vivo quantitative and pharmacokinetic data were 
obtained for the first time for the both enantiomers of [
18
F]FMISO. The R-form showed higher uptake in 
tumor as well as in muscle tissues, thus displaying nearly identical tumor-to muscle ratios and showing 
very similar imaging profiles of both the (S) and the (R)-[
18
F]FMISO enantiomers. 
Graphical abstract 
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Resume 
(på Dansk) 
Formålet med dette Ph.D. projekt var at undersøge overgangsmetal medieret radiofluorinering. 
Hovedmålet for arbejdet var at udvikle en effektiv procedure for radiosyntese af PET 
(positronemissionstomografi) radiolægemidlet [
18
F]FMISO. 
Denne afhandling beskriver det første eksempel på en ’non-carrier added’ overgangsmetal medieret 
enantioselektiv radiofluorinering af epoxider. Tidligere udviklede metoder til effektiv syntese af [
18
F]HF 
(gas) og [
18
F]HF base (vandfri opløsning) foranledigede os til at undersøge omfanget af enantioselektiv 
radiofluorinering af epoxider. Den nyudviklede procedure anvender [
18
F]HF-gas kombineret med en kiral 
base ((-)teramisole), kiral Lewissyre ((R,R)-Co(salen)) og hexafluorisopropanol til at give (S)-
[
18
F]fluorohydriner enantioselektivt (20-46% enatiomerisk overskud) med høje udbytter (78-93% 
radiokemisk udbytte). 
PET radiolægemidler med alifatiske 
18
F-C fragmenter fremstilles typisk ved nukleofil substitution af 
alkoholderivater med [
18
F]KF/Kryptofix 2.2.2, hvilket kan føre til epimerisering. Vores metode tillad os at 
udvikle en direkte et-trins radiosyntese af den vigtige PET hypoxi tracer [
18
F]FMISO via kinetisk 
adskillelse af det korresponderende epoxid. Vi udviklede en effektiv solid-phase-ekstraktionsbaseret 
oprensningsmetode, som tillod os at undgå HPLC oprensning og minimere den samlede radiosyntesetid 
(1.5 t, 45% RCY end of bombardment).  
Eftersom alle nuværende tilgængelige metoder for syntese af [
18
F]FMISO giver en racemisk blanding af 
isomerer, involverede vi os i dyreforsøg for at opklare om de to enantiomerer af [
18
F]FMISO viser 
forskellige biologiske aktiviteter og/eller billeddannelsesegenskaber. 
Dette arbejde gjorde det klart, at der er minimal forskel på R og S isomererne: (R)-isomeren viser højere 
tumoroptag i forhold til (S)-formen af FMISO. Muskeloptaget var også højere for (R)- [
18
F]FMISO, men 
tumor-til-muskel forholdet var det samme for begge isomerer. 
Resultaterne fra in vivo musestudierne viste den samme adfærd for R og S formerne af [
18
F]FMISO, 
hvilket betyder at stereokemien ikke har nogen indflydelse på PET billedkvaliteten af hypoxiske tumorer. 
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Chapter 1 
Short introduction to PET 
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1.1 Multidisciplinary nature of Positron Emission Tomography 
Over the years positron emission tomography (PET) has become an essential research and medical 
imaging modality. PET is one of the most specific and sensitive imaging modalities for studying molecular 
pathways and molecular interactions in the living human body. 
PET is essential imaging modality that combines imaging, cyclotron production of radionuclides, 
radiosynthesis and radiopharmacology. The multidisciplinary nature of radioimaging and PET include the 
collaboration and proficiency of chemists and radiochemists, medical staff, physicists and medical 
physicists, radio-pharmacologists, radio-physicists, biologists, and engineers. 
However, the key to the PET research program will be the development and synthesis of novel innovative 
radiopharmaceuticals with appropriate pharmacokinetics and pharmacodynamics that can follow the 
aspects of physiological and pathophysiological processes. 
1.2 PET imaging 
PET is a type of a non-invasive medical imaging modality that produces functional rather than anatomical 
images, thereby providing greater insight to the patient’s condition. PET is non-invasive, sensitive, 
quantitative method with application in cardiology
1
, oncology
2
, metabolic imaging
3
, neurology
4
, neuro-
oncology and neurological diseases
5
. 
Why PET is so attractive? Nuclear medicine imaging with PET offers valuable functional/physiological 
information, whereas computer tomography (CT) or magnetic resonance imaging (MRI) demonstrates 
exquisite anatomic detail. With PET-CT or PET-MRI, function and structure can be viewed together, 
providing impressive insight into human disease. 
Entry 
Imaging 
modality 
Form of energy 
used 
Spatial resolution, 
mm 
Clinical    Animal 
Acquisition 
time, frame, 
s 
Probe mass 
required, ng 
Sensitivity of 
detection, 
mol/L 
Depth of 
penetration, 
mm 
1 PET 
Annihilation 
photons 
3-8 1-3 1-300 1-100 10
-11
-10
-12
 >300 
2 SPECT γ-photons 5-12 1-4 60-2000 1-1000 10
-10
-10
-11
 >300 
3 CT X-rays 0.5-1 0.03-0.4 1-300   >300 
4 MRI RF waves 0.1-0.2 
0.025-
0.1 
50-3000 10
3
-10
6
 10
-3
-10
-5
 >300 
5 Ultrasound 
High frequency 
sound 
0.1-1.0 0.05-0.1 0.1-100 10
3
-10
6
  1-200 
Table 1. In vivo imaging modalities
6
. 
In cardiology, PET offers unique possibilities in cardiovascular imaging
7
, in particular accurate and 
quantitative assessment of myocardial blood flow and the identification of myocardial viability. The most 
important clinical applications in cardiology are the assessment of myocardial perfusion and metabolism
8
. 
The measurement of the myocardial blood flow under rest and stress conditions
9
 with [
13
N]ammonia and 
 11 
[
15
O]H2O and the energy consumption with 2-deoxy-2-[
18
F]fluoro-D-glucose ([
18
F]FDG, Scheme 1) is a 
standard examination in order to discriminate between ischemic and infarcted tissue
10
. 
 
Scheme 1. 2-Deoxy-2-[
18
F]fluoro-D-glucose. 
PET cardiology viability imaging determines how much heart muscle has been damaged by heart disease 
or a heart attack
11
. Cardiac imaging with PET provides a high degree of diagnostic accuracy, a higher 
temporal and spatial resolution, and a well-established methodology for attenuation correction
11
. PET 
images can be analyzed qualitatively or semi-quantitatively
12
. Unlike conventional cardiac imaging, PET 
studies can also provide absolute quantification of myocardial blood flow in absolute terms (mL/g per 
minute), which cannot be determined by other nuclear imaging methods (SPECT, MRI imaging etc.). 
 
 
Figure 1. Combined PET-CT whole-body images (CT scan, PET image and their superposition PET-CT). 
From the beginning of 1990s, PET imaging of brain tumors has become a standard treatment at many 
medical centers
13,14
. PET is being increasingly used in clinical neurology to improve understanding of 
disease pathogenesis, to complement the diagnosis, and to monitor disease progression and response to 
treatment
15
. 
PET is an extremely powerful method allowing early diagnosis of brain metastasis, distinguishing local 
recurrences from radiotherapy induced changes and detecting malignant transformation of low grade 
tumors, early and presymptomatic diagnosis of individuals at risk for neurodegenerative disorders such as 
Alzheimer’s disease and Parkinson’s disease
16,17
. 
 12 
 
 
 
  
Figure 2. PET-MRI head image. 
As well as a standard radio tracer for everyday clinical use (e.g. [
18
F]FDG showing glucose metabolism, 
and H2
15
O for examining cerebral blood flow), specific tracers were made to illustrate the particular brain 
functions – [
18
F]-6-fluorodopa (or [
18
F]-L-DOPA, Scheme 2). 
 
Scheme 2. [
18
F]-6-fluorodopa. 
PET is essential for oncological application because it visualizes molecular events in living human tissue, 
gives an understanding of the biological characteristics of tumor tissue. Its diagnostic accuracy is 
generally higher than that of the conventional imaging technique of magnetic resonance imaging (MRI), 
and PET result may facilitate more appropriate therapeutic planning for cancer patients. For example, 
[
18
F]FDG-PET scanning of lung cancer had a sensitivity of 96.8% and a specificity of 77.8% (compiled 
data from 4 years of work, and selected 40 studies for inclusion, based on the analysis of almost 1500 
total focal pulmonary lesions)
18
. 
[
18
F]FDG PET has become routine in evaluating patients with lymphoma
19
 (Figure 3). 
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Figure 3. [
18
F]FDG PET-CT whole-body images showing widespread hypermetabolic lymphadenopathy. 
[
18
F]FDG PET scans are more sensitive in assessing for viable tumor in both nodal and extranodal sites, 
with sensitivities ranging from 72% to 100% as opposed to 63–83% for gallium
20,21
. SPECT (single-
photon emission computed tomography) is less sensitive than [
18
F]FDG PET when disease is small or 
involves extranodal sites such as the skeleton or the spleen. From a practical standpoint, [
18
F]FDG PET 
scanning can be done in 1 day instead of the 2–7 days required for gallium imaging. Radiation dose is 
also significantly less – roughly one fourth compared to gallium studies
22
. 
Multiple studies have demonstrated that [
18
F]FDG PET imaging is more accurate than conventional 
anatomic imaging (CT or MRI) for staging melanoma
23
 and breast cancer imaging
24
. 
 
Figure 4. [
18
F]FDG PET study of breast cancer. 
PET and PET-CT imaging has been found particularly helpful at the time of diagnosis of head and neck 
cancer - results can provide biopsy and surgical guidance, which may result in fewer false-negative 
findings and more accurate surgical staging. Several studies have compared PET to CT and MRI for the 
non-invasive staging of regional nodes, with surgical neck dissection as the gold standard
25,26
. 
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Figure 5. PET-CT [
18
F]FDG scanning of a male patient, with left inferior internal jugular node metastases. 
Warm colors (red) correspond to intense radiotracer uptake. 
The accuracy and effectiveness of PET imaging in colorectal cancer has been well studied. The 
information provided by PET-CT is likely to combine the best imaging features of both modalities and 
become the gold standard for staging in colorectal carcinoma
27
. 
[
18
F]FDG PET does have superior sensitivity in detecting of thyroid cancer relative to other nuclear 
medicine techniques
28
. 
Hypoxia in tumors is a serious problem in developing feasible treatment methods. Hypoxic cancer cells 
are known to be more resistant than aerobic cells to ionizing radiation and chemotherapy. The ability for 
noninvasive PET imaging to examine the hypoxia status in tumors with radiolabeled hypoxic tracers 
(Scheme 3) seems to be really challenging compared to old invasive techniques. Its high spatial 
resolution, high sensitivity, and advantages for visualizing molecular events in living tissue made this tool 
very useful
29
. 
 
Scheme 3. PET hypoxia radiopharmaceuticals [
18
F]FMISO, [
18
F]FETNIM, [
18
F]FAZA, and 
64
Cu-ATSM. 
In summary, PET has many advantages over existing imaging techniques for the diagnosis – it is a very 
high sensitivity and a high negative predictive value for lesion detection as compared to classical 
modalities like computed tomography (CT), ultrasonography (USG) and magnetic resonance imaging 
(MRI). PET – is the most specific and sensitive functional diagnostic imaging device for cancers (tumors 
and metastasis) and brain diseases. Image information, obtained from PET, helps to establish the 
treatment plan (surgery, chemotherapy, radiation/proton/ion therapy). Prospects of PET are only limited 
by the development of tracers with adequate specificity to characterize pathology. 
 15 
1.3 Principles of PET 
PET is an imaging technique in which a radionuclide is synthetically introduced into a molecule of 
potential biological relevance and administered to a patient. Depending on the nature of the so-called 
radiopharmaceutical, it may be inhaled, ingested, or, most commonly, injected intravenously. The 
subsequent uptake of the radiotracer is measured over time and used to obtain information about the 
physiological process of interest
30
. 
Because of the high-energy (γ-ray) emissions of the specific isotopes employed and the sensitivity and 
sophistication of the instruments used to detect them, the two-dimensional distribution of radioactivity 
within an organ slice may be inferred from outside of the body. Thus, PET is both emission and 
tomographic (Greek tomos - cut) technique. 
PET uses proton-rich radionuclides with a deficiency of neutrons. Unstable nuclides with an excess 
number of protons may reduce their net nuclear positivity by two approaches. The first one occurs when 
certain proton-rich radionuclides may capture an orbiting electron, transforming a proton to a neutron
31
. 
The resulting daughter nucleus often remains residually excited. This metastable arrangement 
subsequently dissipates, thereby achieving a ground state and producing a single γ-photon in the 
process. Isotopes that decay by electron capture and/or γ-emission are used in SPECT, and include, 
among others 123-iodine (
123
I) and the long-lived metastable nuclide 99m-technetium (
99m
Tc)
32
. 
  
Figure 6. Basic principles and components of a gamma camera
33
 (left). SPECT slice of the distribution of 
99m
Tc within a patient's brain (right). 
The many advantages of SPECT imaging (standardized protocols, large evidence base for diagnostic 
accuracy, risk stratification, guiding patient management) made it widely available. Nonetheless, the 
disadvantages of traditional rest/stress SPECT (the typical protocol is inefficient, often taking 3 to 5 hours 
to complete) limit this method
34,35
. 
An alternative to γ-emission is a situation when a proton is converted to a neutron and a particle called a 
positron (e
+
), which is the event utilized in PET. With identical mass but opposite charge, positrons are 
the antimatter equivalent of electrons. When ejected from the nucleus, a positron collides with an 
electron, resulting in the annihilation of both particles and the release of energy. The principles of 
conservation of mass and momentum dictate that two γ-photons are produced, each of equivalent energy 
 16 
of 511 keV and in directions at approximately 180° from each other. For this reason, PET is sometimes 
referred to as dual photon emission tomography
36
. 
The positron travels a short distance in tissue before the annihilation reaction occurs. This results in some 
degree of uncertainty about the exact location of its origin. In addition, the annihilation photons may 
actually be emitted at angles slightly different than the theoretical 180° - up to 0.25°.These limitations 
contribute to the inherent degradation of spatial resolution in all PET detector systems. However, even 
given these limitations, the spatial resolution in PET imaging is still superior to that seen in imaging with a 
gamma camera for other nuclear medicine examinations
37
. 
 
 
Figure 7. Positron emission and annihilation. 
PET imaging offers many advantages compared to SPECT such as image quality, diagnostic accuracy, 
interpretative certainty, lower dose, and shorter protocol (for example, a rest-stress PET study using 
82
Rb 
can be completed in 20 to 30 minutes). 
The spatial signature of back-to-back photon paths is used by PET scanners in locating the source of an 
annihilation event, a method known as coincidence detection. A PET scanner may be conceptualized as 
a ring-like camera that surrounds the patient. PET scanners employ highly sensitive scintillation detectors 
made of dense crystalline materials (bismuth-germanium oxide, sodium iodide, cesium fluoride) which 
capture the invisible, high-energy γ-rays and convert them into visible light. This flash of light is converted 
into an electrical pulse by a photomultiplier tube (PMT). The crystal and PMT together make up a 
radiation detector. Rather than using individual detectors in isolation, a PET camera is constructed such 
that opposing detectors are electronically connected. Thus, when separate scintillation events in paired 
detectors coincide (3- 10 ns), an annihilation event is presumed to have occurred at some point along an 
imaginary line between the two. This information is registered by a computer and later used to reconstruct 
images using the principles of computed tomography. Conversely, single events are ignored. Although it 
is conceivable that two unrelated photons from spatially separate annihilation events might reach 
opposing detectors in unison, these accidental coincidences are much less frequent than true ones. In 
fact, coincidence detection is a very efficient technique that gives greater sampling rates and 
sensitivity
38,39
. 
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Figure 8. Scheme of positron decay in PET. 
One limitation derives from the nature of positron decay - PET recognizes a place of positron annihilation 
but not the site of radioactive decay. Since a positron must generally come to rest in tissues before being 
able to collide with an electron, annihilation often occurs some distance away from the positron's origin. 
The distance separating these two events, decay and annihilation, depends on the energy of the positron 
as it leaves the nucleus, and varies according to the specific isotope involved. For 
18
F decay, this range is 
2.4 mm. In addition, if the positron is not entirely at rest at annihilation, photons will be emitted at an angle 
slightly different than 180°. Taken together, remote positron annihilation and photon noncolinearity place 
a theoretical limit on PET's achievable spatial resolution, which is estimated at 2–3 mm. Typical clinical 
scanners have a resolution of approximately 4-7 mm
40
. 
PET isotope 
Mean range, 
mm 
Max range, 
mm 
11
C 1.03 3.9 
13
N 1.32 5.1 
15
O 2.01 8.0 
18
F 0.64 2.4 
68
Ga 2.24 8.9 
82
Rb 4.29 16.5 
Table 2. Mean and maximal range of positrons in water. 
Before this resolution was achieved, PET scanners technique passed a long way from 1950, when the 
whole concept of PET imaging was developed and first setups were built. 
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Figure 9. The first PET scanner for brain imaging (1952). 2D-images were obtained by moving opposed 
sodium iodide crystal detectors. Scans of patient with recurring brain tumor. Coincidence scan (a) of a 
patient showing recurrence of tumor under previous operation site, and unbalance scan (b) showing 
asymmetry to the left
41
. 
The first commercial PET scanner was introduced in 1978; during the 1970s and 1980s PET was mainly 
used for research. First approval (FDA, US Food and Drug Administration) was done in 1998. To increase 
the resolution and the sensitivity, new types of detectors have been attempted. To get 3D images, rings of 
detectors surrounding the patient, were advanced. Usually detectors are 18-40 rings of crystals forming a 
cylindrical field of view about 15 cm long that can acquire many slices of coincidence data. A progress in 
personal computers and information storage devices resulted in improved attenuation correction and 
image reconstruction with newer detectors. 
Figure 10 shows the evolution of image quality from the first Siemens manufactured PET scanner PET III, 
commercially available in 1975, to the quite sophisticated model from 1995, ECAT Exact HR+. The finer 
details of internal brain structures can be visualized much better in the latest model. This improvement 
has been achieved with a larger number and better radiation sensors, better software and the possibility 
of getting several slices at the same time using many rings of sensors. 
 
 
Figure 11. Increasing of resolution and sensitivity made in PET imaging of brain for the period from 1975 
to 1995, the Siemens biomedical equipment manufacturer (www.siemens.com). 
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As a result, nowadays hospitals and research centers possessing unique instruments with more slices in 
CT, short time of flight, list mode acquisition, gating etc. 
Currently almost all PET scanners are joint with CT scanners because the resolution of PET is relatively 
low and precise anatomical information could be provided well by CT. The useful PET information can be 
accurately localized inside of the body by using the CT scans. But CT gives an additional radiation 
exposure. The use of Magnetic Resonance (MRI) instead of CT eludes this additional radiation exposure. 
For the first time MRI/PET scanners were presented in 2010. MRI is a more flexible imaging modality and 
could provide additional information that is not available with CT. 
  
Figure 12. Siemens Healthcare Biograph mCT/PET scanner – the last generation of PET-CT scanners 
from Siemens, 2008, and PET-CT image obtained from Siemens Biograph mCT, www.siemens.com. 
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1.4 PET isotopes  
Isotopes used for PET have decay half time short enough to not to irradiate the patients, and long enough 
to provide sufficient freedom for the chemists to perform radiolabeling/purification/certification/ delivering 
procedures. In fact, a choice is not so broad – only limited amount of positron decaying nuclei found their 
application in radiopharmacy. 
Table 3. PET isotopes with medical applications, based on Dr. Robert E. Schenter publications
42
. 
Isotope 
Half-life 
time 
Cyclotron 
energy, 
MeV 
Emax(β
+
), 
MeV 
Diagnostic applications* 
Carbon-11 20.3 min 3-16 0.96 Cancers: chest, chronic lymphocytic, glioblastoma, liver, multiple 
myeloma, prostate, urinary tract; diseases: Alzheimer’s, brain, epilepsy, 
heart, Parkinson’s alcohol addiction, amphetamine release, drug 
addiction, neuropsychiatric, nicotine dependence, pain processing, 
schizophrenia, small animal imaging, tobacco addiction 
Nitrogen-13 9.97 min 7-16 1.19 Ammonia dog studies, coronary artery disease, diabetes, gamma 
camera, heart disease, imaging of heart, pancreas and liver, lupus 
erythematosus, myocardial perfusion, pulmonary ventilation 
Oxygen-15 122 s 0-10 1.72 Acute brain injury, arterial blood flow, brain cancer, oxygen utilization, 
brain studies, cerebral blood volume, cerebral responses, coronary 
artery vasospasm, coronary reserve, heart disease, ischemic stroke 
disease, kinetics of oxygen, liver cancer, myocardial viability, oxygen 
metabolism, pain control, venous ulceration 
Fluorine-18 1.83 h 3-16 0.635 Cancers: adrenal gland, anal, bone, bone marrow transplants, bowel, 
breast, cervical, chest, colorectal, esophageal, gastric, head and neck, 
Hodgkin’s disease, laryngeal, leukemia, liver, lung (NSCLC), lung 
(SCLC), melanoma, multiple myeloma, non-Hodgkin’s lymphoma, 
osseous, ovarian, pancreatic, prostate, rectal, Rhabdomjo sarcoma, 
squamous cell, thyroid, urinary, vocal cord; diseases: alcohol addiction, 
Alzheimer’s, anorexia, atherosclerosis, brain, depression, diabetes, 
heart, herpes, HIV, hypoxia, infection, liver, muscle, narcolepsy, lung 
inflammation, osteomyelitis, Parkinson’s, pneumonia, ulcerative colitis, 
schizophrenia, Tourette’s syndrome infection: pen-prosthetic, hip-
prosthetic, joint-prosthetic small animal imaging, chemotherapy research 
Iron-52 8.28 h 192 0.8 Anemia, human bone marrow 
Copper-62 9.74 min 21-26 2.93 Cerebral and myocardial perfusion, colorectal cancer, biodistribution, 
liver cancer, renal blood flow, renal injury 
Copper-64 12.70 h 5-18 0.65 Cancers: cervical, colon, colorectal, lymphoma, melanoma, pancreatic, 
prostate; diseases: angiogenesis, brain, hypoxia, Parkinson’s, Wilson’s 
stem cell research 
Gallium-68 1.13 h 13-22 1.89 Breast cancer, heart imaging, immunoscintigraphy, molecular imaging, 
neuroendocrine tumors, pancreatic cancer 
Bromine-76 16.0 h 10-16 3.4 Anti-carcinoembryonic antigens, anti-CEA antibodies, DNA studies, 
nerves of the heart, quantitative imaging 
Rubidium-82 1.26 min 40-60 3.35 Heart disease, myocardial perfusion, sarcoidosis 
Yttrium-86 14.74 h 10-15 1.54 Distribution of Y-90, lung cancer, melanoma, renal cell carcinoma 
Zirconium-89 3.27 d 5-18 0.90 Brain tumors, head and neck cancers, non-Hodgkin’s lymphoma 
Iodine-124 4.18 d 13-16 2.10 Apoptosis, cancer biotherapy, glioma, heart disease, mediastinal 
micrometastates, scouting of therapeutic radioimmunoconjugates, 
thyroid cancer 
First four isotopes in this list are the most common and the most important. The production energies 
required for these PET isotopes are low (usually around 5 to 20 MeV). A half-life is rather short, high 
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doses could be produced with short labelling processes. An external production and delivery to PET 
installations without a cyclotron are presently only established for 
18
F-radiotracers
43
. 
1.5 PET isotopes production 
Radiopharmaceuticals are used as radioactive tracers for the diagnosis and treatment of patients. George 
Charles de Hevesy published the first paper on the radioactive tracer concept in 1913. He coined the term 
radioindicator or radiotracer and introduced the tracer principle in biomedical sciences. An important 
characteristic of a tracer is that it can facilitate the study of components of a homeostatic system without 
disturbing their function. In 1924, the tracer concept paved the way for the use of radioisotopes as 
diagnostic tools. In 1927, the US physicians Hermann Blumgart and Soma Weiss injected solutions of 
bismuth-214 (
214
Bi) into the veins of men to study the velocity of blood. 
After the discoveries of the cyclotron by Ernest Lawrence in 1931 and artificial radioactivity by Irène Curie 
and Jean-Frédéric Joliot in 1934, it was possible to make practically every imaginable radioisotope for 
use in diagnostics or in therapy. Isotopes such as iodine-131 (
131
I), phosphorus-32 (
32
P) and cobalt-60 
(
60
Co) are already used in diagnostics and therapy since the mid-1930s
44
. 
Ernest Lawrence recognized the medical potential of radioisotopes. His brother, John Lawrence, a 
hematologist, helped research the field’s potential and established and administered the therapeutic 
procedures. In 1936 he treated a leukemia patient using cyclotron produced 
32
P. It was the first time that 
a radioisotope had been used in the treatment of a disease, marking the birth of nuclear medicine. 
Of the many different radionuclides used in diagnostic procedures, only a few are valuable in diagnosing 
cancer. PET-CT is currently accepted to be the most accurate way to stage and monitor many types of 
cancer. It is used routinely in detecting tumors of thyroid and primary or metastatic tumors. Globally, the 
vast majority of these investigations are performed using the glucose analogue [
18
F]FDG. 
There are two methods to produce medical isotopes – irradiation of a target material in nuclear reactor 
and bombardment of target with beams of accelerated particles in a cyclotron. Cyclotrons have a number 
of advantages over nuclear reactors for radioisotope production, such as safety, cheaper operating and 
decommissioning costs. Because cyclotrons are powered by electricity rather than the uranium fission 
reaction of a nuclear reactor, they generate far less waste compared to research reactors. 
Generally, medical isotopes are produced by cyclotrons - a particle accelerator which produces positron-
emitting elements or short-lived radioisotopes. The cyclotron bombards non-radioactive elements in the 
target with accelerated particles, which converts these elements into positron-emitting radioactive 
isotopes. The production of radionuclides with an accelerator demands that particle beams be delivered 
with two specific characteristics. The beam must have sufficient energy to bring about the required 
nuclear reactions, and there must be sufficient beam current to give practical yields. 
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Accelerator production of radioisotopes reached its turning point with the construction of the first cyclotron 
by Lawrence, Edlefsen and Livingston in 1930. The first cyclotron dedicated to medical applications was 
installed at Washington University, St Louis, in 1941, where radioactive isotopes of phosphorus, iron, 
arsenic and sulfur were produced
45
. 
Cyclotrons are the most commonly used devices for acceleration of particles to energies sufficient for 
bringing about the required nuclear reactions. It was the remarkable idea of E. Lawrence to bend the path 
of the particles into a circle and therefore to use the same electrode system over and over again to 
accelerate the particles. This idea is the basis of all modern cyclotrons, and has made the cyclotron the 
most widely used type of particle accelerator. The first model was built in 1930, with proof of particle 
acceleration being provided by Livingston in 1931. 
According to the theory of electrodynamics, the rotational frequency of a charged particle travelling in a 
magnetic field is independent of the radius of its orbit. The energy of the particle increases as the velocity 
of the particle increases. The cyclotron utilizes this fact to produce particles of reasonably high energy in 
a relatively confined space. The acceleration chamber of the cyclotron is placed between the poles of a 
homogeneous magnetic field (Figure 12). 
  
Figure 12. Principle of a cyclotron (left). GE PETtrace cyclotron installed in the Hevesy laboratory (right). 
The cyclotron magnetic field causes particles to travel in circular orbits. Ions are produced in an ion 
source at the center of the machine and are accelerated out from the center. The ions are accelerated by 
a high frequency electric field through two or more hollow electrodes called ‘dees’. The ions are 
accelerated as they pass from one dee to the next through a gap between the dees. Since the rotational 
frequency of the particles remains constant as the energy of the particles increases, the diameter of the 
orbit increases until the particle can be extracted from the outer edge of the machine. The limit on the 
energy of a particle is determined on a practical basis by the diameter of the magnet pole face
46
. 
Carbon-11, nitrogen-13, oxygen-15 and fluorine-18 – are the most common isotopes for PET clinical use. 
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Isotop 
Cyclotron reaction, 
target material 
Decay mode Radiopharmaceuticals References 
Carbon-11 
14
N(p,α)
11
C 
14
N2 - gas 
99.8% β
+
, 
0.2% EC 
[
11
C]acetate, [
11
C]methionine, N-
methyl-[
11
C]flumazenil, [O-methyl-
11
C]-raclopride 
47 
Nitrogen-13 
16
O(p,α)
13
N 
16
O-water 
100% β
+
 
[
13
N]ammonia, 
[
13
N]N2 
48, 49 
Oxygen-15 
14
N(d,n)
15
O 
14
N2 - gas 
99.9% β
+
 
H2
15
O-water, 
[
15
O]O2, 
[
15
O]CO 
50, 51, 52 
Fluorine-18 
20
Ne(d,α)
18
F 
Ne – gas 
or 
18
O(p,n)
18
F 
18
O-water
 
96.9% β
+
, 
3.1% EC 
[
18
F]FDG, [
18
F]NaFe, [
18
F]FDOPA,
 
[
18
F]FLT, [
18
F]Flutemetamol, 
[
18
F]FMISO 
53, 54, 55 
Copper-64 
64
Ni(p,n)
64
Cu 
64
Ni – solid metal, 
electroplated
 
17.9% β
+
, 
39.0% β
-
, 
43.1% EC, 
0.5% γ/IC 
64
Cu-ATSM (diacetyl-bis(N4-
methylthiosemicarbazone)) 
56, 57 
Table 4. Most important PET isotopes. 
Sometimes long lived positron emitting radionuclides are commercially available or obtainable from 
research facilities with larger accelerators. Some examples of longer lived positron emitting radionuclides 
are 
52
Fe (t½ = 8.3 h), 
55
Co (t½ =17.5 h) and 
124
I (t½ = 4.2 d). Sometimes also positron emitting 
radionuclides can be obtained from a generator system. Examples are 
82
Rb (t½ = 76 s) from 
82
Sr (t½ = 
25.5 d) and 
68
Ga (t½ = 68 m) from 
68
Ge (t½ = 270 d). Although all these radionuclides are used, the 
isotopes of the biological most important elements receive most attention. 
1.5.1 Production of fluorine-18 
Among different radioisotopes, biopharmaceutically and PET-friendly [
18
F]-fluorine is currently the most 
widely used. Radioactive 
18
F has a half-life 109.8 min - long enough to 
11
C, 
13
N or 
15
N. This fact allows for 
commercial distribution of 
18
F-radiopharmaceuticals. 
18
F is almost pure β+ emitter (96.9% β+, 3.1% EC) 
with endpoint energy of 0.635 MeV and maximal positron range 2.4 mm in water. These properties make 
18
F an ideal candidate for radiolabelling. 
18
F-fluoride could be produced in nuclear reactors or in cyclotrons. An interesting example is the 
production of 
18
F from nuclear reactor
58,59 
by starting with neutrons to generate tritons which induce a 
charged particle reaction in a nuclear reactor: 
6
Li(n,
3
H)
4
He  
16
O(
3
H,n)
18
F 
By the irradiation with neutrons, tritons are generated by the breaking up of the 
6
Li into a tritium and a 
helium-3 nucleus. The triton is than able to produce 
18
F from the 
16
O-nucleus. Because of the 
incorporation of the oxygen inside the molecule, the range of the tritons is not essential. Since this is a 
two-stage process the yield is lower (30 mCi) than the yields achievable with direct reactions as can be 
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done with charge particle induced reaction. The practical difficulties are significant, not least because of 
the need to isolate the product from tritium and lithium. 
Cyclotron production of 
18
F has two main directions. A first method for the production of 
18
F is carrier 
added (CA) reaction 
20
Ne(d,α)
18
F. The 
18
F becomes available as F2 and the relative low specific activity 
depends on the amount of fluorine (0.1-0.2%) added before irradiation
60
. 
The bombardment of high pressure neon (up to 25 bar) containing a low percentage (0.1-0.2%) of 
molecular fluorine with moderate energy deuterons is now a common and well-established method for 
producing CA molecular 
18
F-fluorine
53,54
. 
The most common modern way to produce NCA 
18
F is the 
18
O(p,n)
18
F reaction with H2
18
O (oxygen-18 
95% enriched water) as target material. The 
18
F is available as fluoride ion in water. This is the most 
effective method for the non-carrier added 
18
F-fluoride. After separation of the fluoride from the water, the 
fluoride is available for chemistry. The water can be reused after distillation to eliminate impurities. The 
enrichment grade will diminish of course by the distillation procedure. The specific activity of the 
fluorinated end product can easily be better than carbon-11 product because fluoride is less abundant 
than e.g. CO2. 
The beam energy required for (p,xn) reaction follows a rule of thumb: 7 + 10*xn MeV with xn the number 
of neutrons to be knocked out. For an exact calculation one should calculate the mass difference and add 
roughly 7 MeV for the maximum cross section. 
 
 
Figure 13. Schematic view of the NCA 
18
F target and synthesis unit. 
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The targets may use approx. 1-2 mL of 
18
O-enriched water. Target materials containing chromium, iron or 
cobalt are undesirable, as they possibly produce unreactive 
18
F-fluorides, but nickel, titanium, niobium 
and silver are acceptable. 
18
O-enriched water is expensive; it can be re-used after distillation or after 
recovery of 
18
F-fluoride, for example, by adsorption on an anion exchange column or cartridge. The 
process is intrinsically high yielding. Very high specific activities can be achieved from fluoride-free water. 
 
Figure 14. Cyclotron high beam current target for 
18
F
-
 production. 
For the nucleophilic processes the 
18
F
-
 is required as ‘naked’ non-carrier added fluoride i.e. in the 
absence of water. Several procedures have been described for the recovery of NCA fluoride in a reactive 
form from 
18
O-enriched water. The strategy for generation of reactive 
18
F is generally dissolution of the 
18
F-fluoride with a large counterion (Cs
+
, Rb
+
, Bu4N
+
 or K
+
/Kryptofix) in a polar aprotic solvent. Where 
required, water (or other solvent) is removed by distillation from an added base (e.g. KOH, K2CO3, 
Rb2CO3, Et4N
+
OH
-
, Bu4N
+
OH
-
 or K2CO3-Kryptofix) by azeotropic distillation with acetonitrile or even by 
microwaves. This salt is then solubilized in the solvent containing the substrate for nucleophilic attack. 
Resolubilization efficiency is affected by the reaction vessel, solvent and other factors such as metal ion 
contamination. The intrinsic reactivity of the 
18
F-fluoride is affected by several factors, including cation and 
anion contaminants whose level is largely determined by the materials of target construction and 
operation. Cations, especially Al
3+
, and Ca
2+
, are probably most detrimental to successful chemistry
55,61
. 
Among this variety of isotopes, currently, 
18
F – is the most used isotope because of advantages listed 
below: 
- the decay positrons are relatively of low energy and therefore have short ranges in the body, 
- high specific activities can be produced, 
- the labeled tracers are structurally very similar to their non-labeled counterparts. 
Possessing these unique properties, 
18
F chemistry has one disadvantage – introducing of 
18
F into new 
molecules can be problematic. 
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1.6 PET radiopharmaceuticals 
The most important need for further utilization of PET imaging is the development of new 
radiopharmaceuticals. Molecular imaging with radiopharmaceuticals can be used for a wide ranging of 
applications, like drug development, pharmacokinetics studies, clinical investigations, and routine 
diagnostics. 
Some of radiopharmaceuticals for molecular imaging of biochemical processes such as metabolism, 
specific receptors, blood flow, perfusion and hypoxia are listed below. Each radiopharmaceutical focuses 
on specific target of each biochemical or biological process
62
. For example, the most known and the most 
widely used PET radiopharmaceutical [
18
F]FDG - also called “the molecule of the millennium”. [
18
F]FDG 
can target the enzyme, hexokinase, and specifically measure the glucose metabolism in vivo. Many 
attempts of the [
18
F]FDG synthesis were tried before the major breakthrough was done in 1986 by 
Hammacher et al., who developed a method with high radiochemical yield (RCY) and short total time of 
synthesis. 
Table 5. Main PET radiopharmaceuticals for clinical use. 
Acronym / name Structure 
Biochemical 
process 
Specific target Ref. 
[
18
F]FDG 
18
F-fluorodeoxyglucose 
 
 
Sugar 
metabolism 
Hexokinase 
63, 64, 
65, 66, 
67 
[
18
F]NaF 
18
F-Sodium Fluoride 
Na
18
F 
Fluoride 
metabolism 
 68 
[
18
F]FDOPA 
3,4-dihydroxy-6-
18
F-fluoro-
L-phenylalanine 
 
 
Dopamine 
methabolism 
Aromatic amino 
acid 
decarboxylase 
69, 70 
[
18
F]FLT 
3'-Deoxy-3'-(18)F-
fluorothymidine 
 
DNA 
synthesis 
Thymidine kinase 
71, 72, 
73 
[
18
F]FLM 
18
F-Flumetamol or Vizamyl 
 
 
Apoptosis Phosphatidylserine 74 
[
18
F]FCH 
18
F-fluorocholine 
 
 
Cellular 
ligand 
transport 
Choline kinase 75 
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[
18
F]FET 
18
F-fluoroethyl-L-tyrosine 
 
 
Amino acids 
methabolism 
Protein synthesis 76 
[
18
F]FES 
18
F-fluoro-b-estradiol 
 
 
Tumor 
receptors 
Estrogen receptor 61 
[
18
F]FMISO 
1H‐1‐(3‐[18F]‐fluoro‐2‐
hydroxy‐propyl)‐2‐
nitroimidazole 
 
 
Hypoxia 
Acidic pH and 
reductive potential 
77 
[
18
F]FAZA 
18
F-fluoroazomycin 
arabinoside 
 
 
Hypoxia 
Acidic pH and 
reductive potential 
78 
64
Cu-ATSM 
64
Cu-diacetyl-bis N4-
methylthiosemicarbazone 
 
 
Hypoxia 
Acidic pH and 
reductive potential 
79 
 
[
18
F]FDG, [
18
F]NaF, Amyvid™ and Vizamyl™ are FDA (United States Food and Drug Administration) 
approved imaging radiopharmaceuticals. The first and the most important radiotracer from this list 
[
18
F]FDG - FDA announced  to be safe and effective for certain indications when produced under 
conditions specified in approved applications (March 2000). 
Synthesis, quality control and regulations of [
18
F]FDG became a model in the development of new 
radiopharmaceuticals. The conception of using robots or automatic synthesis modules is a standard in 
PET radiochemistry of modern time. Many others radiopharmaceuticals were developed using the same 
strategy - for example [
18
F]FET ([
18
F]fluoroethyl-L-tyrosine), [
18
F]FCH ([
18
F]fluorocholine), [
18
F]FMISO 
([
18
F]fluoromisonidazole), [
18
F]FES ([
18
F]fluoro-β-estradiol). 
The development of new tracers with even better properties, tracers labelling specific sites, evolving of 
new methods and procedures is therefore still a highly prioritized research area. 
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1.7Challenges and directions of modern radiofluorination 
Elemento- and organometallic chemistry and improving of radiofluorination 
PET has been always limited by chemistry. New methods for the synthesis of radiolabeled molecules 
have the prospective to impact clinical PET imaging only if they can be successfully translated. However, 
progression of modern reactions from the stage of synthetic chemistry development to the preparation of 
radiotracer doses ready for use in human PET imaging is challenging and rare. 
Once chemistry with 
18
F is feasible (i.e. a fluorination reaction can be accomplished with 
18
F, and a RCY 
can be determined), the reaction still may not lead to a practical synthesis method for molecules useful for 
PET imaging experiments. Most importantly, radiochemistry techniques must allow for efficient purification 
due to time constraints. The formation of constitutional isomers that are difficult-to-separate must be 
minimized during synthesis, and starting materials as well as byproducts must be removable from the 
desired sample. Final samples must be radiochemically and chemically pure, sterile and endotoxin free. 
Additionally, a substantial quantity of radioactivity must be obtained at the end of synthesis.
80
 
1.7.1 Fluoride recovery and processing 
Fluoride has high hydration energy, so water is not a suitable solvent for Sn2 radiofluorination. Polar 
aprotic solvent such as acetonitrile should be used in Sn2 nucleophilic substitution reaction. Since 
18
F
-
-
fluoride is produced via a 
18
O(p,n)
18
F reaction, it is necessary to isolate the 
18
F-ion from its aqueous 
environment. 
 
Scheme 4. Synthesis of [
18
F]FDG by nucleophilic substitution 
The most convenient way to separate is to use a light QMA (quaternary ammonium anion exchange) 
Sep-Pak column. The 
18
F
-
 is retained by or via an ion-exchange reaction and allowed the 
18
O-water to 
flow through. The retained 
18
F
-
 is then eluted with an acetonitrile solution of Kryptofix and potassium 
carbonate. Evaporation of the acetonitrile in a nitrogen atmosphere will remove any residual [
18
O]H2O 
escaped into the reaction vial together with the 
18
F
-
. The automatic synthesizers perform this step several 
times to ensure all residual water is removed.
64
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Figure 15. Potassium - Kryptofix complex [N(CH2CH2OCH2CH2OCH2CH2)3N]K 
The overall procedure of 
18
F
-
 recovery and activation requires several liquid and gas transfers resulting in 
lengthening of synthesis, reduced yields, and complex automation. Significant efforts focused on 
eliminating the azeotropic evaporation step. 
[
18
F]HF transfer 
An alternative to a conventional 
18
F-K/Kryptofix method is recovery and processing
81
 of 
18
F-fluoride via 
gaseous [
18
F]HF. This method was developed in our laboratory and successfully used in radiofluorination. 
We found that the reaction of target water with H2SO4 (98-100%) allowed to recover of up to 82% of 
18
F-
fluoride as [
18
F]HF-gas or [
18
F]HF·amine/base solution in anhydrous organic solvent
82
. Home-made 
glassy carbon and PE devices for transfer were made to perform this experiment. 
 
Figure 16. Schematic view of [
18
F]HF generator. 
 
Scheme 5. 
The [
18
F]HF distillate is acid-free but slightly moist (5180 ppm after 30 min of distillation) – even this 
moisture content is not crucial for most of experiments. High and reproducible transfer of [
18
F]HF could be  
achieved under vigorous argon flow (up to 400 ccm) and ultrasound irradiation
83
.  
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This method was used for the synthesis of a series of phosphazenium hydrofluorides, P1
tBu
[
18
F]HF, 
P1
Oct
[
18
F]HF, P2
Et
[
18
F]HF, and P4
tBu
 [
18
F]HF. 
High specific activity and excellent radiochemical yields with various substrates (Table 6) suggest that the 
proposed radiofluorination methodology can complement the current [
18
F]KF/Kryptofix methods in the 
areas for which nonpolar reaction conditions are required
83
. 
Reagent Substrate RCY, % 
P2
Et
[
18
F]HF 2-(naphthalen-1-yl)ethyl methanesulfonate 91 
P2
Et
[
18
F]HF 2-(naphthalen-1-yl)ethyl 4-methylbenzenesulfonate 82 
P4
tBu
 [
18
F]H FDG precursor 82 
Table 6. Radiofluorination with [
18
F] phosphazenium hydrofluorides. 
 
Ionic liquids 
Ionic liquids are novel promising materials that consist of very lipophilic cations and their counter anions 
having melting points below ambient temperature. This symbiosis of unique physical and chemical 
properties, made ionic liquids to be considered as alternative green chemistry reaction media, in contrast 
to the classical organic solvents. Ionic liquids as powerful media for organic reactions, because they can 
accelerate reaction rates, improve selectivity, and facilitate catalyst recovery. 
 
Scheme 6. 
Some model halo- and mesyloxyalkanes can be fluorinated to the corresponding fluoroderivatives via 
nucleophilic fluorination in the presence of KHCO3 or Cs2CO3 in [bmim][OTf]. The main benefit from the 
use of ionic liquids is that 
18
F
-
 in target irradiated [
18
O]H2O can be added directly to the reaction mixture 
instead of following long protocol of dehydration procedures
84
. 
Polymer supported radiofluorination (PSRF) 
Probably a more attractive approach involves radiofluorination performed directly on the solid phase 
extraction (SPE) media. One of the first examples of PSRF was described with 4-aminopyridinium salt on 
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a polymer support. This resin is a phase transfer catalyst, that eliminates the need of toxic Kryptofix, 
simplifies purification and remove the need for fluoride elution and azeotropic evaporation The possibility 
of “polymer supported” radiofluorination was described before, but the aminopyridine-based resin gave 
poor stability and inconsistent 
18
F
−
- trapping and radiofluorination
85,86
. 
A new method was developed in our group – PSRF with the polymer supported phosphazene bases PS-
P2
tBu
 and the novel PS-P2
PEG
 which allowed for efficient extraction of [
18
F]F
−
 from irradiated water and 
succeeding radiofluorination of a broad range of substrates directly on the resin. This method could be 
characterized by high radiochemical yields (up to 70% with aliphatic sulfonates and 42% with bromides) 
and a short time (30–45 min) of the total radiosynthesis. The resins could be reused several times with 
the same or different substrates. 
 
 
Figure 17. Scheme of automated radiosynthesis module for on-column radiofluorination and some 
18
F-
products obtained via this method
87
. 
The fully automated on-column radiofluorination methodology was applied to the radiosynthesis of the 
important PET radiotracers [
18
F]FLT and [
18
F]FDG (40% RCY on a 120 GBq scale, all GMP-regulated 
quality control tests, required for commercial production of [
18
F]FDG, were passed). 
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Scheme 7. Selection of radiofluorinated products, obtained using PSRF. 
The combination of compact form factor, simplicity of 
18
F-fluoride recovery and processing, column 
reusability can make solid phase radiofluorination an attractive radiochemistry platform for the emerging 
dose-on-demand instruments for bedside production of PET radiotracers.
87
 
1.7.3 Expanding the substrate scope and selectivity with transition metals 
The synthesis of 
18
F-radiotracers used for PET imaging is different compared to the conventional 
19
F-
fluorination. Translation from 
19
F to 
18
F is challenging and significantly more complicated and 
unpredictable than would be anticipated from the synthesis of an ordinary isotopologue. Concentration 
and reaction conditions, most notably stoichiometry, dramatically change as a consequence of the 
nanomolar amount of 
18
F-fluoride used in radiosyntheses. An excellent 
19
F fluorination reaction may not 
necessarily be suitable for 
18
F chemistry
88
. 
It is important to introduce the short half-life radioisotope 
18
F as late and as rapidly as possible in the 
synthetic system to achieve maximal RCY. Moreover, 
18
F-fluorination should ideally be performed using a 
18
F-fluoride source in preference to [
18
F]F2 or other derivatives of electrophilic fluorine, as most PET 
centers are not equipped with gas targets and gaseous reagents. Also, the specific activity of [
18
F]F2 is 
low (440 GBq/mmol) compared to that achievable using [
18
O]water/[
18
F]fluoride target technology (3.7·10
5 
GBq/mmol). 
Fluoride is the most abundant form of fluorine. Extremely powerful nucleophile and base, fluoride 
completely loses its reactivity in water due to enormous free energy of hydration. This “hydration penalty” 
will influence both the kinetics and overall thermodynamics of nucleophilic fluorination. Can the transition 
metals (TM) alleviate this penalty by trading TM-fluorophilicity for fluoride hydrophilicity? 
Fluorinations catalysed by transition metals have been extensively scrutinized and reviewed, especially 
reactions employing electrophilic fluorinating reagents ([
18
F]DOPA for example). On the other hand, 
transition metal catalysed fluorination with nucleophilic fluorinating reagents is an emerging area in 
catalysis. The successful development of transition metal catalysed fluorination is directly dependent on 
the availability of competent, soluble fluoride sources and a clear understanding of the parameters that 
control nucleophilicity vs basicity. 
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Recent developments in transition metal catalysed processes have enabled the nucleophilic fluorination 
of substrates that could not be fluorinated in the absence of catalysts. 
Pd-mediated radiofluorination of aryls 
Transition metal mediated fluorination to the formation of 
18
F-aryl bonds from 
18
F-fluoride has recently 
been validated. Ritter et al. have established a synthesis of a Pd
IV
 [
18
F]fluoride from [
18
F]fluoride that can 
be used as an electrophilic fluorinating reagent of high specific activity. Potentially this could provide a 
route to previously unattainable PET tracers as the fluorination step is no longer limited to nucleophilic 
methodologies.
89
 
The synthesis is shown to give decay-corrected radiochemical yields (RCY) up to 33% in 10 min, with an 
overall reaction time of 60 minutes. 
 
 
Scheme 8. Synthesis of an electrophilic fluorinating reagent from nucleophilic fluoride. 
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Scheme 9. Synthesis of 
18
F aryl fluorides. 
An electrophilic radiofluorination for the synthesis of aryl fluorides with high specific activity makes use of 
Pd
IV
 complex to incorporate 
18
F-fluoride into arenes. The Pd
IV
 complex captures fluoride and then 
functions as an electrophilic 
18
F-fluorination reagent. An advantage of this method is that [
18
F]fluoride can 
be incorporated into functionalized arenes at a late stage. Moreover, the Pd
IV
-[
18
F] complex is thermally 
stable and insensitive to water
90
. 
Nevertheless, this method has disadvantages. Pd-compounds are very expensive; making the end 
product more costly than it is already. Also a need to be separated at the end of the synthesis and too 
complicated synthetical route limit practical use of this method in routine radiopharmacy/radiochemistry 
practice. 
Pd-mediated radiofluorination in allylic position 
Another transition metal mediated synthesis of 
18
F-radiolabelled compounds was described by 
Gouverneur et al
89
. An attractive route to allylic fluorides is the Pd(0)-catalyzed Tsuji–Trost allylic 
alkylation with fluoride as the nucleophilic reactant
91,92
. This reaction is a very powerful transformation for 
the attachment of a variety of carbo- and heteroatom nucleophiles to allylic electrophiles. Togni et al
93
 
investigated the feasibility of a Pd-catalyzed allylic nucleophilic fluorination in 2006. It was found that 
exposure of cationic Pd(II) allyl complexes to various fluoride sources at room temperature and showed 
no conversion to allylic fluoride. 
Further studies of this reaction in “cold” 
19
F variant demonstrated that allylic fluorination of allyl carbonates 
with TBAF·4tBuOH is feasible
89
. A p-nitrobenzoate was identified as a superior leaving group to 
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carbonate, an interesting observation since the use of this leaving group in classical palladium chemistry 
is sparse in the literature
94
. 
 
Scheme 10. Pd
0
-catalized fluorination of allylic para-nitrobenzoates. 
For the radiochemistry work, the methyl carbonate was found to be the superior leaving group. 
 
Scheme 11. Pd
0
-catalized radiofluorination of carbonates. 
Iridium variant of this reaction was reports by Nguyen et al
95
. Secondary and tertiary racemic allylic 
fluorides from allylic trichloroacetimidate under iridium catalysis (5 mol% (Ir(COD)Cl)2). Triethylamine 
trihydrofluoride ( Et3N·3HF or TREATHF) was found to be the optimized source of fluoride allowing 
moderate to good yields of secondary branched allylic fluorides to be obtained. Tertiary allylic fluorides 
though accessible by this route could not be isolated owing to polymerization or decomposition. 
 
Scheme 12. Ir-catalyzed fluorination of allylic trichloroacetimidates. 
This rapid and functionally tolerant reaction has also been extended to the preparation of a representative 
18
F-allylic fluoride in 38% RCY (decay-corrected). 
 
Scheme 13. Ir-catalyzed radiofluorination. 
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Ir or Pd catalysts are expensive, this adds to the overall cost of the synthesis. This method has almost no 
practical use in radiopharmacy. In fact, no relevant radiopharmaceuticals could be produced via this 
method. 
Ni-mediated radiofluorination 
The ability to use aqueous fluoride solutions makes extensive drying procedures, which are typical for 
radiochemistry with [
18
F]fluoride, excessive. Drying procedures increase the time from 
18
F-production to 
tracer purification; drying fluoride for the [
18
F]FDG takes 20-30 min. The direct use of aqueous fluoride 
solution could avoid loss of activity and also increases the RCY because of drying fluoride absorption 
onto walls of glass reaction vessels. 
The one-step oxidative fluorination of well-defined nickel complexes with oxidant and aqueous fluoride 
enables a straightforward and practical 
18
F late-stage fluorination of complex small molecules. The ability 
to use aqueous solutions of 
18
F-fluoride is remarkable
96
. 
 
 
Scheme 14. Ni
II
 complexes for the radiofluorination in aqueous media and 
18
F-labelled aryl fluorides. 
Radiofluorination takes place at room temperature and is complete within less than one minute. Ni
II
 aryl 
pyridylsulfonamide complexes can be oxidized with oxidant in the presence of aqueous [18F]fluoride to 
afford complex 
18
F-labeled arenes in 13–58% radiochemical yield. The use of an aqueous 
18
F solution 
obviates the need for time-consuming anion-exchange and azeotropic drying steps during the synthesis 
of the PET tracer
96
. 
The disadvantage of this method is complicated multistep synthetic route, which also makes it expensive. 
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Chapter 2 
Co(salen)-mediated enantioselective radiofluorination of epoxides 
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2.1 Transition metal mediated fluorination of epoxides 
Incorporated into organic molecules C-F bond modulate useful properties like lipophilicity, bioavailability, 
and oxidative stability. Introduction of fluorine into organic molecules is a challenging field of 
elementoorganic chemistry. New methods for the formation aliphatic C-F bonds have the potential to 
deliver chiral fluorinated structures inaccessible from commercial or biogenic sources
97
. 
Opening of epoxides with fluoride can provide access to fluorinated secondary or tertiary carbon centers. 
Stable solutions of HF with amines such as pyridine·nHF and Et3N·3HF are suitable for the ring opening 
of epoxides, but usually gave poor yields of racemate. When used in combination with Lewis acids, 
problems arise due to competitive uncatalyzed pathways and catalyst inhibition. 
Historically, asymmetric opening of meso-epoxides with fluoride was first reported by Haufe et al
98,99,100 
with stoichiometric amounts of chiral Lewis acid complexes. Haufe desymmetrized cyclohexene oxide 
using KHF2/18-crown-6 in the presence of 1 eq. of (S,S)-(+)-(salen) chromium chloride complex in DMF at 
60 
o
C. 
Scheme 15. 
Trans-2-fluorocyclohexanol was formed in 55% ee in mixture with trans-2-chlorocyclohexanol (20% ee). 
Using 0.1 eq. of CrCl(salen), the ee of the fluorohydrin decreased to 11%. These reactions constitute the 
first enantioselective nucleophilic fluorination by desymmetrization of meso-epoxides
98
. 
When subjected to fluorination, the racemic epoxide styrene oxide and phenyl glycidylether led to 
preferential attack of the fluoride at the less substituted carbon. The products of these reactions were 
formed in 90% and 62% ee respectively. 
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Scheme16. 
Different fluoride sources were investigated. Silver fluoride was found to be a superior reagent, preventing 
the formation of undesired chlorohydrin and delivering the fluorocyclohexanol, fluorocyclopentenol and 
fluorocycloheptanol with ee of 72%, 44% (75% conversion) and 65% (82% conversion) respectively. 
These reactions need to use 1 eq. or at best 0.5 eq. of the metal complex
99,100
. 
 
Scheme 17. 
Mezzetti et al
91
 investigated the enantioselective desymmetrization of meso epoxides in 2009, trying to 
define a more efficient catalytic system. Cyclopentene oxide underwent ring opening with AgHF2 in the 
presence of 0.2 eq. of either ([RuCl(PNNP)2]PF6) or the dicationic complex ([Ru(OEt2)2(PNNP)](PF6)2) 
(PNNP = 3,5-bis(diphenylphosphinomethyl)pyrazol). The best results were obtained by slow addition of 
the epoxide to a solution of 0.2 eq. ([Ru(OEt2)2(PNNP)](PF6)2) in CH2Cl2 and 2 eq. of AgHF2. 
 
Scheme 18. 
Under these conditions, the ring opened fluorinated product was isolated in 11% yield and 25% ee. 
Competing polymerization was responsible for the low isolated yield of this transformation. Alternative 
fluoride sources such as Et3N·3HF, (Bu4N)H2F3, KHF2 and PhCOF led only to epoxide polymerization or 
gave no conversion at all
91,92
. 
The most recent development in this area was done with a Co
III
-salen catalyst by Kalow and Doyle
101,97
 
for meso-epoxides and terminal epoxides.HF was generated in situ upon addition of 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP) to benzoyl fluoride in the presence of an amine catalyst. An asymmetric 
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variant of this protocol was successfully implemented (yields up to 88% and ee ranging from 58% to 95%) 
performing the hydrofluorination of various meso epoxides in TBME using both the chiral isothiourea (-)-
tetramisole (8 mol%) and the chiral Co(salen) complex (10 mol%) as a catalysts
101
. 
 
Scheme 19. Assymetric fluorination of meso epoxides by Doyle. 
The limitation of this chemistry is the long reaction time (24–120 h). Control reactions with achiral amines 
or the use of a mismatched Lewis acid/amine pair had a detrimental impact both on yield and 
enantioselectivity, an observation supporting the synergic cooperative effect of the two chiral cocatalysts. 
Meso cyclic epoxides containing alkene, ester and protected amine functionalities were all amenable to 
hydrofluorination under the optimized reaction conditions or slightly readjusted variants (t-AmOH or 
diethylether as the solvent). When applied to racemic terminal epoxides, kinetic resolution took place 
delivering the fluorohydrins (regioselective opening at the terminal position) with ee 88 - 99%. 
Further studies
97
 shed light on the mechanism of this hydrofluorination. The rate limiting step, the fluoride 
ring opening event, is proposed to proceed via a bimetallic mechanism based on kinetics non-linear effect 
studies
102
 with monomeric Co(salen) catalysts and experiments using a linked catalyst: 
 
Scheme 20. 
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A kinetic profile with apparent first-order dependence on Co(salen) was observed. To account for these 
data, the authors propose a mechanism involving a cobalt fluoride as the active nucleophilic fluorine 
species that forms a resting state dimer. In this mechanistic scenario, axial ligation of the amine 
cocatalyst to Co(salen) can facilitate dimer dissociation and is accounting for the observed cooperativity. 
Taken together, these insights led to the strategy of a second generation dimeric catalyst displaying 
dramatically improved efficiency (shorter reaction time)
 97
. 
 
 
Scheme 21. Improved protocol of enantioselective fluorination of epoxides via kinetic resolution by Doyle. 
The nitroimidazole-substituted fluorohydrin represents the “cold” version of the PET hypoxia imaging 
radiotracer fluoromisonidazole FMISO. 
 
Scheme 22. 
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2.2 Results and discussions 
Transition metal-mediated asymmetric hydrofluorination of epoxides, pioneered by Haufe
98
 has been 
developed into a highly efficient catalytic system by Doyle and co-workers
101
,
97
. The translation of 
transition metal mediated 
19
F-chemistry into no carrier added (NCA) radiofluorination has so far been 
limited
103,104
. Although the nucleophilic epoxide opening with 
18
F-fluoride has received attention over the 
years the efficient reaction remains challenging and the yields vary significantly. 
2.2.1 Preparation of [18F]HF 
Doyle et al used benzoyl fluoride as a latent source of HF. The combination of benzoyl fluoride and HFIP 
generates HF in situ: 
 
Scheme 23. 
Benzoyl fluoride is manufactured from benzoyl chloride and KF via Halex reaction. Similar methodology 
could be used for the synthesis of [
18
F]PhCOF, but will lead to low RCY, time extension of the radio 
synthesis and extra complication of setup (GC separation is needed)
105
. 
In our opinion, since the real fluorinating agent is HF but not PhCOF, there is no real need to synthesize 
[
18
F]PhCOF. Even in cold variant of this reaction, PhCOOCH(CF3)2 is produced in excess and makes the 
separation difficult. 
Anhydrous hydrogen fluoride HF is one of the cheapest fluorinating reagents. But the low boiling point 
(19.6 
o
C) of this highly corrosive acid leads to logistic challenges, which highly limits its use in laboratory 
practice. Stable solutions of HF with amines have been reported. In the mid-seventies, Olah and 
coworkers demonstrated that pyridinium poly-hydrogen fluoride is a stabilized highly versatile reagent for 
the fluorination of a large range of functional groups
106
. Various neutral reagents have been developed. 
Previous research from our group has shown that 
18
F-fluoride can be efficiently recovered from irradiated 
target 
18
O-water as H
18
F gas
82,83
. To obtain [
18
F]HF in a high yield and purity, efficient degassing of the 
reaction mixture is needed. This can be achieved using vigorous argon flow and ultrasound irradiation. 
HF is known as an extremely corrosive and etching substance for many materials, common in laboratory 
practice - especially for glass and stainless steel. This fact resulted in a search for suitable material, 
compatible with automation module. In the preliminary experiments polyethylene (PE) vials/vessels and 
tubing were used for construction of kits for HF transfer. Later we found polypropylene (PP) vials and 
tubing could be used with similar success. Our final variant of setup was however performed from Teflon 
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(PTFE) and perfluoroalkoxy polymer (PFA). This setup showed robustness and excellent HF transfer (up 
to 95% in 15-30 min). Argon was more efficient for HF-transfer than helium. 
In our experiments H
18
F was generated by adding 
18
O-enriched cyclotron-irradiated water to 98-99% 
sulfuric acid followed by ultra sound irradiation at 80-85 
o
C. The flow of argon carried the liberated 
hydrogen fluoride to a trapping vial charged with a solution of organic base.  
 
 
Figure 18. Scheme of [
18
F]HF generator. 
After this step regular glassware and reaction vessels could be used for further reactions. Importantly, 
[
18
F]HF generator was integrated into remotely controlled robot, used later to produce [
18
F]FMISO from 
60-70 GBq of cyclotron produced 
18
F. With [
18
F]HF in hand we were ready for further studies. 
2.2.2 Preliminary studies 
In our preliminary experiment, [
18
F]HF (-)tetramisole (prepared as described above), was reacted with 9-
oxabicyclo[6.1.0]non-4-ene in the presence of chiral (R,R)-Co(salen) and hexafluoroisopropanol (HFIP) in 
tert-butyl methyl ether (TBME): 
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Scheme 24. 
18
F-hydrofluorination of 9-oxabicyclo[6.1.0]non-4-ene using [
18
F]HF/(-)-tetramisol and (R,R)-
Co(salen). 
After 1 h at 100 
o
C radio-TLC analysis showed that the corresponding 
18
F-fluorohydrin was obtained in 
78% radiochemical conversion (RCC). The enantioselectivity was only 32%, as measured by the normal 
phase chiral radio-HPLC performed on a Chiralpak AD-3 column. 
As expected, lowering the reaction temperature led to an increase in enantioselectivity and dropping of 
RCC. No reaction was observed at room temperature (Table 7). 
Entry 
18
F-fluorohydrine t, °C RCC, % ee, % 
1 8-fluorocyclooct-4-enol 100 78 33 
2 8-fluorocyclooct-4-enol 75 25 48 
3 8-fluorocyclooct-4-enol 50 5 - 
4 8-fluorocyclooct-4-enol 25 0 - 
Table 7. 
The mismatched Lewis acid enantiomer (S,S)-Co(salen) under the same conditions gave the ent-
fuorohydrine in only 36% RCY and 27% ee (Table 8). It seems to be a cooperative effect in catalysis. 
Entry Catalyst RCC, % ee, % 
1 (R,R)-Co(salen) 78 33 
2 (S,S)-Co(salen) 36 27 
3 phenylene-Co(salen) 55 0 
4 (R,R)-Co(salen)OTs 0 - 
Table 8. 
Non-chiral variant of phenylene-Co(salen) showed lower conversion compare to chiral (R,R)-Co(salen). 
The pre-oxidized form of the catalyst like Co
III
(salen)OTs was ineffective in the absence of HFIP. 
Oxidation of Co(salen) with tBuOOH (similar system was described by Doyle et al) offered no 
radiofluorination as well. 
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Synthesis of Co(salen) catalysts 
We started our experiments with Co(salen) purchased from Strem Chemicals, but because we were not 
able to reproduce the yields of our experiments with commercially available Co(salen), we used Co(salen) 
that was synthesized according to the procedure described below. It seems like impurities of Co(OAc)2 in 
the catalyst are most likely critical for the successful radiofluorination. We used a 5% excess of a chiral 
salen-ligand in our method instead of using excess of Co
II
. The whole synthesis was performed as a one 
pot procedure (Scheme 25). 
 
Scheme 25. 
Non-chiral Co(salen) made from 1,2-phenylenediamine instead of chiral 1,2-cyclohexanediamine was 
synthesized by the same route (Scheme 26): 
 
Scheme 26. 
Co
III
(salen)OTs was synthesized from the corresponding Co
II
(salen) precursor according to the described 
procedure
107
 (Scheme 27): 
 
Scheme 27. 
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2.2.3 Screening of alcohol additives 
We found that HFIP, used in the earlier work to facilitate the release of HF from benzoyl fluoride, was 
essential for successful radiofluorination. A control experiment where [
18
F]HF was introduced into the 
reaction mixture without HFIP yielded no 
18
F-fluorohydrin. Different alcohols were tried instead of HFIP. 
These alcohol additives, varying in acidity and steric bulk, were noticeably less effective than HFIP. While 
the role of hydroxylic additives is unclear at the moment, there seemed to be a pronounced ‘‘fluorous’’ 
effect, as the RCC increased when the fluorinated analogs were used (Table 9, entries 2 and 3, 4 and 5, 
6 and 7). To prove the absence of carrier effect (due to possible traces of cold fluoride in HFIP), HFIP was 
purified by a sequential passing through basic alumina and silica, followed by vacuum distillation. This 
purification had no discernible effect on either the RCY or the specific activity of the product. The pKa of 
the protic additives did not seem to play a major role in the ‘‘fluorous’’ effect as phenol (pKa = 10) 
remained inferior to HFIP (pKa = 9.3). 
Entry R-OH pKa RCY, % 
1 None  < 1 
2 HFIP 9.3 78 
3 iPrOH 16.5 3 
4 tBuOH 17.0 5 
5 (CF3)3COH 5.2 26 
6 PhOH 9.9 5 
7 C6F5OH 5.5 16 
Table 9. 
The effect of HFIP was also prominent under the “cold” fluorination conditions. The freshly prepared cold 
HF (-)-tetramisole used in combination with Co(salen) gave the desired fluorocyclohexanol in 95% yield 
within 2 h. Without HFIP the reaction took two days to reach the same level of conversion. Based on 
these observations we believe that HFIP kinetically facilitates hydrofluorination by acting on one or more 
catalytic Co(salen) species. 
 
Scheme 28. 
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2.2.4 Screening of bases and solvents 
A few nitrogen bases were tested, but only (-)-tetramisol was effective. Other bases, such as DBU, DBN, 
Et3N and pyridine, showed no conversion of [
18
F]F
-
 at all. The strong cooperative effect of Co(salen)/base 
on RCY and enantioselectivity was observed earlier
101,97
. We have also confirmed that for 
radiofluorination. The mismatched enantiomer ent-(S,S)-2 gave the product in only 36% RCC and 27% 
ee. 
Entry Solvent RCC, % ee, % 
1 CH3CN, DMF, DMSO  <1  
2 THF, EtOH, (H3C)2CO <1  
3 TBME 78 32 
4 tAmOH 50 68 
Table 10. 
Aprotic solvents are usually preferred for this kind of reactions, because nucleophilicity and reactivity are 
severely inhibited by the influence of the hydrogen bonds of protic solvents. Other solvents used for Sn2 
fluorination/radiofluorination like acetonitrile, DMF, DMSO resulted in no radiofluorinated products at all. 
THF, EtOH and acetone showed no conversion either. 
On the other hand, our experimental systems with TBME showed high conversion of radioactive fluoride. 
Changing the solvent from TBME to tAmOH resulted in lower yield but higher enantioselectivity. A 
remarkable effect of using tertiary alcohols as a reaction medium for nucleophilic substitution was 
described previously for the fluorination and radiofluorination with alkali metal fluorides
108
. Hindered protic 
solvents like tert-butanol and tert-amyl alcohol are more promising compared to the aprotic solvents. 
tBuOH could not be used in our experiments as a solvent (but was tried as an additive showing 5% RCC) 
because of the high melting point (25 
o
C) – and thus it was not possible to trap gaseous H
18
F at low 
temperatures. But tAmOH with a low melting point at -9 
o
C and a high boiling point of 101-103 
o
C seems 
to be an excellent solvent for our reaction. Almost no loss of alcohol was observed during the transfer of 
H
18
F. 
2.2.5 Screening of substrates 
The substrate scope of 
18
F-hydrofluorination was investigated by reacting a substrate with a mixture of 
[
18
F](-)-tetramisole hydrofluoride, (R,R)-Co(salen), and HFIP in TBME at 100 
o
C (Table 11). The RCYs for 
desymmetrization of the meso epoxides were uniformly high. However, the enantioselectivities were only 
moderate-to-low, most likely due to the high reaction temperatures required for opening of cyclic 
epoxides. This was consistent with the moderate 52% ee obtained after applying the cold protocol to 
cyclopentane oxide. Surprisingly, terminal polycyclic aromatic epoxides proved to be challenging 
substrates. The 1-naphthalenyloxirane was unreactive, and 9- anthryloxirane gave unidentified products. 
Our attempt to make “cold” fluorohydrine from these substrates also failed as no signals of desired 
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products were observed (
19
F and 
1
H NMR spectroscopy) (Table 11, entries 4 and 5). It looks like epoxides 
undergo polymerization as all NMR-signals were broadened. 
Entry Epoxide RCY, % ee, % 
1 
 
73 20 
2 
 
93 45 
3 
 
78 33 
4 
 
<1 - 
5 
 
<1 - 
Table 11. 
2.2.6 Stereochemistry studies 
An important question concerns the absolute configuration of radiofluorinated products. Due to nanomolar 
amounts of 
18
F, this can lead to different stoichiometry and mechanism. Because of nanomolar 
concentrations of 
18
F-fluorohydrines, any approaches to the direct determination of the absolute 
stereochemistry of radiolabeled substrates are not usable. An indirect method, based on comparison of 
chromatography parameters (Rf for thin layer chromatography and retention time rt for HPLC methods) of 
18
F-radiofluorohydrin derivatives with their 
19
F-isotopomers, for which absolute configuration could be 
reliably established using classical methods, was applied. To determine the absolute configuration the 
following “hot” and “cold” experiments were made in parallel. 
The (R,R)Co(salen)-mediated fluorination and radiofluorination of meso epoxides (cyclopentene oxide, 
cyclohexene oxide, cyclooctadiene oxide yielded the corresponding isotopomeric fluorohydrins and 
18
F-
fluorohydrins. These had identical rt values as measured by normal phase chiral HPLC/radioHPLC 
(Scheme 29). The reaction of “cold” and “hot” fluorohydrines with (R)-(-)-α-methoxy-α-
(trifluoromethyl)phenylacetyl chloride was fast and complete within minutes giving the corresponding 
Mosher esters in high diastereoselectivity (de > 95%). 
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Scheme 29. 
The “cold” diastereomers can be resolved by the standard reverse-phase HPLC. The Mosher 
derivatization of the corresponding “hot” fluorohydrins resulted in radio-HPLC-resolvable diastereomeric 
18
F-isotopomers. “Cold” and “hot” Mosher esters had identical HPLC/radioHPLC retention times, thus 
establishing the same absolute configuration. 
To determine the absolute configuration we performed Mosher ester and enzymatic resolution studies. 
 
2.2.6.1 NMR Mosher esters experiments 
The absolute stereochemistry of 8-fluorocyclooct-4-enol, 2-fluorocyclohexanol and 2-fluorocyclopentanol 
was assigned using NMR spectroscopy methods via derivatization of fluorohydrines with two enantiomers 
of α-methoxy-α-trifluoromethylphenylacetyl chloride (MTPACl). 
The esters of these fluorohydines were prepared according to the described method
109,110
. 
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Scheme 30. 
The difference in shifts from 
13
C and 
19
F NMR spectra was insignificant. 
1
H NMR method in combination 
with 2D 
1
H-
1
H COSY and 
1
H-
13
C HSQC was applied. Shifts of corresponding protons were distinguished 
and identified from 
1
H NMR. When overlapping of signals was observed, the shifts were estimated from 
2D NMR spectra. 
 
Scheme 31. 
Procedure of distinguishing and identifying of proton shifts: 
- from HSCQ spectra -FCH- and =CHO- protons can be reliably assigned; 
- from COSY spectra coupling between =CHO- proton and neighboring –CH2- can be found. 
For both fluorohydrins the Δδ
SR
 values are clearly positive or negative. 
Entry Fluorohydrine Proton Δδ
SR
 
Carbon 
configuration 
1 2-fluorocyclopentanol 
-FCH- 5.06-4.96 = 0.10 (pos.) 
S 
-CH2-HCO- 
2.18-2.21 = -0.03 (neg.) 
1.63-1.79 = -0.13 (neg.) 
2 2-fluorocyclohexanol 
-FCH- 4.48-4.39=0.09 (pos.) 
S 
-CH2-HCO- 1.34-1.48= - 0.14 (neg.) 
3 8-fluorocyclooct-4-enol 
-FCH- 4.78-4.70=0.08 (pos.) 
S 
-CH2-HCO- 
2.10-2.17= - 0.07 (neg.) 
1.72-1.86= - 0.14 (neg.) 
Table 12. Determination of absolute stereochemistry by 
1
H NMR using Mosher esters. 
 51 
1
H NMR of Mosher ester from 2-fluorocyclohexanol was also modeled
*
. The computational model was in 
agreement with our experiment. 
The conformational search on the Mosher ester structures was performed using MM2 force field. The top 
scoring poses were optimized at B3LYP/6-31G* level as implemented in Jaguar 8.1. All structures were 
verified to be minima on the potential energy surfaces by vibrational analyses. The NMR shielding were 
calculated using DFT calculations with GIAO method at BLYP/cc-VTZ level using Gaussian 09 suite of 
programs. 
 
 
Figure 19. Models of R and S Mosher esters of (S,S)-2-fluorocyclohexanol. 
Proton 
Δδ
SR
 
experimental 
Δδ
SR
 
theoretical 
Carbon 
configuration 
-FCH- 4.48-4.39=0.09 (pos.) 0.36 (pos.) S 
-CH2-HCO- 1.34-1.48= - 0.14 (neg.) 
-0.29 (neg.) 
-0.27 (neg.) 
S 
Table 13. Experimental and theoretical values of 
1
H shifts for 2-fluorocyclohexanol Mosher esters. 
  
                                                          
*
The computational model was made by F. Zhuravlev 
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2.2.6.2 Lipase-catalyzed deracemization of 2-fluorocyclohexyl acetate 
In addition to Mosher esters studies we performed enzymatic deracemization to prove independently the 
formation of (S,S)-stereoisomer of 2-fluorocyclohexanol from the reaction of meso-epoxide with (R,R)-
Co(salen).
111
 
Enantiomericaly enriched 2-fluorocyclohexanol was synthesized from meso-cyclohexene oxide according 
to the procedure described by Doyle
101
, applying (R,R)-Co(salen) as a chiral catalyst and (-)-tetramisole 
as a chiral base. 
 
Scheme 32. 
Racemic 2-fluorocyclohexyl acetate was prepared via acylation of corresponding fluorohydrine with acetic 
anhydride in pyridine. This ester was then involved into the reaction with PCL lipase
111
 (water, phosphate 
buffer), providing us with material for GC analysis (chiral cyclodex-B column (30 m × 0.25 mm) was 
used). 
 
Scheme 33. 
The GC traces of the two enantiomericaly enriched samples were compared. From the fact that 
enzymatic hydrolysis of racemic acetate forms (R,R)-fluorohydrine while keeping (S,S)-acetate unreacted, 
the stereochemistry of (R,R)-Co(salen) catalyzed reaction was shown to be (S,S). 
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Table 14. Chiral GC traces from lipase-catalyzed deracemization of 2-fluorocyclohexyl acetate 
(conditions: cyclodex-B column (30 m × 0.25 mm), 80 °C, isotherm (40 min), FID detector). 
Entry Chiral GC trace Description 
1 
 
Racemic 2-
fluorocyclohexanol 
(0% ee) 
2 
 
(S,S)-2-
fluorocyclohexanol 
(32% ee) 
3 
 
Racemic 2-
fluorocyclohexyl 
acetate  
(0% ee) 
4 
 
Racemic 2-
fluorocyclohexyl 
acetate after lipase: 
 
(R,R)-2-
fluorocyclohexanol 
(94% ee) 
 
(S,S)-2-
fluorocyclohexyl 
acetate  
(99% ee) 
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2.2.6.3 Resolution of fluorohydines with chiral amino acids derivatives 
With no access to chiral HPLC and GC at the beginning of our study, we have developed radio-TLC 
based methodology for resolution of enantiomeric fluorohydrines. 
 
Scheme34. 
Fluorohydrins were derivatized with hydroxysuccinimide esters of Boc-protected amino acids according to 
the procedure described below, based on the published methods
112,113
. The enantiomeric resolution of 
fluorohydrins has been achieved using C18-silica TLC plates (Analtech). These plates showed the best 
separation compared to the others. Chiral silica and normal silica plates were tried but showed lower 
separation than C18-plates or no separation. Sometimes decomposition of products of acylation was 
observed on normal and chiral silica. For these reasons experiments were made mostly with C18-silica. 
When the separation of enantiomers was poor, long plates (up to 190 mm) were used. 
   
ee 0% - racemic mixture ee 12% ee 48% 
Figure 20. Radio TLC traces of the derivatives fluorohydrines. 
It is important to make the starting sport not too large, since a larger spot makes it harder to see the 
diastereomers separation after running the plate. Various developing solvents can be used to develop the 
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plate. The completed TLC plates were then analyzed under UV lamp (cold standards) and radioTLC 
scanner (Table 15). Various developing components (e.g. solvent, TLC plate, amino acid derivative) can 
be used to define the optimal separation: 
Entry Fluorohydrine 
Amino acid 
derivative 
TLC plate Solvent (v/v) RF1 RF2 RF2/RF1 
1 8-fluorocyclooct-4-enol Boc-Ala-OSu normal 40/60 EtOAc/Hept 0.60 0.66 1.10 
2 8-fluorocyclooct-4-enol Boc-Ala-OSu chiral 40/60 EtOAc/Hept 0.70 0.72 1.03 
3 8-fluorocyclooct-4-enol Boc-Ala-OSu C18 40/60 EtOAc/Hept 0.79 0.85 1.08 
4 8-fluorocyclooct-4-enol Boc-Ala-OSu C18 20/80 EtOAc/Hept 0.53 0.60 1.13 
5 8-fluorocyclooct-4-enol Boc-Phe-OSu normal 20/80 EtOAc/Hept 0.37 0.39 1.06 
6 8-fluorocyclooct-4-enol Boc-Phe-OSu C18 20/80 EtOAc/Hept 0.50 0.55 1.09 
7 2-fluorocyclohexanol Boc-Ala-OSu C18 10/1 Tol/EtOAc 0.569 0.639 1.12 
8 2-fluorocyclopentanol Boc-Ala-OSu 
Boc-Phe-OSu 
norm., C18 
and chiral 
10/1 Tol/EtOAc no separation 
9 2-fluorocyclopentanol 
10 2-fluorocyclopentanol Boc-Pro-OSu C18 5/1 Tol/EtOAc 0.52 0.55 1.07 
11 2-fluorocyclopentanol Boc-Ala-OSu, 
Boc-Phe-OSu 
norm., C18 
and chiral 
Tol/EtOAc, 
CHCl3/CH3CN 
no separation 
12 FMISO 
13 FMISO Boc-Val-OSu C18 1/1 Tol/EtOAc 0.41 0.46 1.12 
14 FMISO Boc-Val-OSu C18 5/1 Tol/EtOAc 0.28 0.33 1.17 
Table 15. RF values for enantiomers, ratio of the RF values, solvent and type of silica TLC plates. 
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2.3 Experimental part 
18
F-Fluoride radiochemistry 
The aqueous solutions of 
18
F-fluoride were prepared by the 
18
O(p,n)
18
F reaction in a GE PET-trace 
cyclotron using a 1.8-mL target of 95% enriched 
18
O-water irradiated by a 14.1-MeV beam at 20–25mA 
for 60–90 min. The transfer was run in an ultrasound bath Sonorex DT52H, operating at 240 W / 35 kHz 
at 80 
o
C (Ar flow 200-400 cm
3
/min). The kit for transfer was constructed using PE, PP or PFA reaction 
vials and PTFE tubing (ID=3.0 mm). 
[
18
F]HF-Transfer procedure 
 
Scheme35. 
First vial of the kit was charged with 5 or 10 mL of conc. H2SO4. The second vial was charged with a 
solution of base ((-)-tetramisole, DBU, DBN, TREAT HF) in 3 or 5 mL of solvent (TBME or 
t
AmOH) and 
cooled down to 0 
o
C (ice bath) A portion of irradiated 
18
O-water or target wash was injected into the first 
vial, followed by blowing with argon (350-400 mL/min), heating (80-85 
o
C) and ultrasound irradiation at 
35kHz (Sonorex DT52H) for 15 to 30 min. Thereafter the second vial was disconnected from the kit and 
the activity of the produced solution was measured (80% RCY). An additional quantity of solvent was 
added. This solution of base/H
18
F was used for further experiments. 
Reference racemic fluorohydrines synthesis 
 
 
Scheme 36. 
A glass ampule was charged with an epoxide (18.4 mmol, 1.0 eq.) and TREAT HF (3.0 mL, 18.4 mmol, 
1.0 eq.), sealed and heated overnight at 80 
o
C. The resulting reaction mixture was crashed with a mixture 
of ice (10 g) and ammonia hydroxide solution (30%, 10 mL), then washed with Et2O (3x20 mL). The 
organic phase was washed with an aqueous solution of HCl (1N, 10 mL) and dried over Na2SO4. The 
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solvent was removed in vacuo. Oil residues were passed through a short SiO2 column (EtOAc/Hexane, 
1/5 to 1/1), which usually gave 80-90% of fluorohydrine as a single product. 
General procedure for radiofluorination of the epoxides 
 
Scheme 37. 
An oven-dried high pressure glass tube equipped with a stir bar was charged with Co(salen) (12.0 mg, 
0.020 mmol) and HFIP (112 μL, 0.80 mmol). The resulting slurry was then stirred for 5 min under air; an 
epoxide (0.20 mmol) was added neat followed by the solution of [
18
F]HF/(-)-tetramisole (4.1 mg, 0.020 
mmol) in TBME (3 mL). The reaction mixture was then heated at 100 
o
C for 1 h. The reaction conversion 
was monitored by radio-TLC. No loss of activity due to volatilization was observed. 
(Salen)-ligand 
 
Scheme 38. 
3,5-Di-tert-butyl-2-hydroxybenzaldehyde (4.10 g,17.5 mmol, 2.0 eq.) was dissolved in 70 mL of dry EtOH, 
then was mixed with a solution of (1R,2R)-cyclohexane-1,2-diamine (1.00 g, 8.75 mmol, 1.0 eq.) in 40 mL 
of EtOH. The mixture was diluted with additional EtOH (50 mL) and refluxed for 1 h under argon. The 
solvent was removed in vacuo; solids (4.60 g, 8.41 mmol, 96%) were dried in deep vacuo overnight. No 
impurities were observed. This compound was used for the next step without further purification. 
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(1R,2R)-(-)-1,2-Cyclohexanediamino-N,N'-bis(3,5-di-t-butylsalicylidene)cobalt(II) (or Co(salen)) 
 
Scheme 39. 
A solution of cobalt(II) acetate tetrahydrate (Co(OAc)2
.
4H2O) (1.94 g, 7.82 mmol, 1.0 eq.) was added via 
cannula to a solution of salen-ligand (4.50 g, 8.24 mmol, 1.05 eq., 5% excess) in CH2Cl2 (40 mL) at room 
temperature under argon. The mixture was stirred for 5 min, and then cooled to 0 
o
C. The red precipitate 
was filtered under argon, washed with cold MeOH (3x25 mL) and dried in vacuo (4.13 g, 6.84 mmol, 
88%). This material was recrystallized from TBME under argon (thin dark red needles, m.p. > 400 
o
C), 
providing Co(salen)-catalyst for radiofluorination experiments. 
2-(Naphthalen-1-yl)oxirane and 2-(anthracen-9-yl)oxirane 
These two epoxides were synthesized via Corey–Chaykovsky reaction from the corresponding aromatic 
aldehydes and trimethylsulfonium iodide
114,115
. 
 
 
Scheme 40. 
A suspension of aromatic aldehyde (13.8 mmol, 1.0 eq.), trimethylsulfonium iodide (3.47 g, 16.6 mmol, 
1.2 eq.), KOH (1.55 g, 27.6 mmol, 2.0 eq.) and water (62 μl, 62.1 mg, 3.45 mmol, 0.25 eq.) in MeCN (50 
mL) was stirred at 60 
o
C for 4 h. The suspension was cooled to rt and diluted with CH2Cl2, filtered over 
celite and the solvent was removed in vacuo to give the product as a yellow solid. 
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Mosher esters procedure 
 
Scheme 41. 
A solution of DMAP (<0.1 mg, cat. amount), Et3N (6.1 μL, 0.0440 mmol, 10eq.) and fluorohydrine (0.0044 
mmol, 1 eq.) in 0.5 mL of dry CH2Cl2 was prepared under argon and transferred into the NMR tubes. (S)-
MTPACl (1.64 μL, 0.0088 mmol, 2 eq.) was added. The NMR tubes were sealed and shaken vigorously 
for 15 min at room temperature. The solvent was freezed and removed in vacuo, CDCl3 (0.6 ml) was 
added and the ampule was sealed under vacuo, providing a sample for NMR studies. The second sample 
with (R)-MTPACl was prepared in exactly the same way. 
 
Scheme 42. 
Acylation of 
18
F-fluorohydrins with hydroxysuccinimide esters of Boc-protected amino acids 
1 mL of “hot” reaction mixture was placed into a vial (10 mL volume) and the solvent was evaporated with 
a flow of argon. 1 mL of CH2Cl2 was then added and blown again to remove the rests of the solvent. The 
resulting “hot” dry residues were dissolved in 1 mL of CH2Cl2. A second glass vial (4 mL vial with screwed 
top) was charged with Sc(OTf)3 (1 eq., 0.04 mmol, 21 mg), DMAP (5 eq., 0.20 mmol, 26 mg) and 0.5 mL 
of CH2Cl2. This mixture was stirred for 5 min at rt. Thereafter “hot” solution from the first vial was added to 
the second. The resulting mixture was stirred for an additional 2 minutes at rt, followed by addition of Boc-
Ala-OSu (5 eq., 0.21 mmol, 60 mg) in one portion. The mixture was stirred for 2 minutes, providing the 
diastereomeric material for radio-TLC. 
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HSQC of (S)-MTPA ester of 8-fluorocyclooct-4-enol (from (R)-MTPACl) 
 
HSQC of (R)-MTPA ester of 8-fluorocyclooct-4-enol (from (S)-MTPACl) 
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COSY of (S)-MTPA ester of 8-fluorocyclooct-4-enol (from (R)-MTPACl) 
 
COSY of (R)-MTPA ester of 8-fluorocyclooct-4-enol (from (S)-MTPACl) 
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HSQC of (S)-MTPA ester of 2-fluorocyclohexanol (from (R)-MTPACl) 
 
HSQC of (R)-MTPA ester of 2-fluorocyclohexanol (from (S)-MTPACl) 
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COSY of (S)-MTPA ester of 2-fluorocyclohexanol (from (R)-MTPACl) 
 
COSY of (R)-MTPA ester of 2-fluorocyclohexanol (from (S)-MTPACl) 
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HSQC of (S)-MTPA ester of 2-fluorocyclopentanol (from (R)-MTPACl) 
 
HSQC of (R)-MTPA ester of 2-fluorocyclopentanol (from (S)-MTPACl) 
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COSY of (S)-MTPA ester of 2-fluorocyclopentanol (from (R)-MTPACl) 
 
COSY of (R)-MTPA ester of 2-fluorocyclopentanol (from (S)-MTPACl) 
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Chapter 3 
Synthesis and biological evaluation of both enantiomers of [18F]FMISO 
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The most important need for further utilization of PET imaging is the development of new 
radiopharmaceuticals and more efficient synthetic routes to already known substances. 
The use of enantiomerically pure compounds is a standard requirement in the pharmaceutical industry, 
and today - also for PET studies. Often pre-existing chirality can be built into a target molecule prior to the 
labeling step (chiral carbon atoms bound to OH and NH2,); a number of syntheses have been developed 
(for example, for amino acids) where asymmetric induction has been achieved using chiral handles, 
stereoselective enzymes or chiral resolution
116
. 
A biological problem can sometimes be solved using PET-labeled enantiomers. For example, the specific 
binding of rolipram to the enzyme phosphodiesterase-4 in the central nervous system is almost 
exclusively observed using the [
11
C]R(-)-rolipram enantiomer, while the [
11
C]S(+)-rolipram enantiomer 
exhibits homogeneous binding in the brain. Since there is no discrete region in the brain which is devoid 
of this enzyme, S(+)-enantiomer be used to estimate the free and nonspecifically bound component of its 
biologically active antipode
117
. 
 
Scheme 43. 
The synthesis of [
18
F]FDG can yield a product which is contaminated with a variable percentage of 2-
fluoro-2-deoxy-D-mannose ([
18
F]FDM), an epimer of [
18
F]FDG. The level of such contamination is ranging 
from 0 to 50%. The presence of FDM as an impurity could result in a significant source of error in 
estimating glucose consumption using the [
18
F]FDG method. 
 
Scheme 44. 
[
18
F]FMISO or [
18
F]fluoromisonidazole is hypoxia PET tracer which is quite often used in preclinical and 
clinical studies. The molecule has a chiral center, but is used for injection as a racemic mixture. 
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Scheme 45. 
To the best of our knowledge nobody tried to investigate the difference between the R and S enantiomers 
for the distributions in major tissues. In this chapter we try to give an answer to the question whether the 
biodistribution and imaging characteristics of [
18
F]FMISO as a PET tracer is connected to its enantiomeric 
purity. 
3.1.1 Hypoxia 
Appropriate radiotracers, especially [
18
F]FMISO, enable non-invasive assessment of hypoxia. Hypoxia is 
a state in which insufficient amount of oxygen is delivered to the tissue. This is a more serious problem 
than realized in clinical routine work. During incidence and progress of many types of diseases hypoxia 
may enhance development and progress of disease and, even more, decrease chances of efficient 
treatment of tumors. 
Oxygen is an essential nutrient for mammalian cells because of its role as the terminal electron acceptor 
in oxidative phosphorylation. Supplied through breathing, O2 dissolves in plasma and tissues and is 
carried throughout the body as oxyhemoglobin, O2Hb, which releases O2 when it is needed for 
mitochondrial respiration. It is so essential to the well-being of cells that intricate control mechanisms 
have evolved to maintain a sufficient supply of O2 for the mitochondria. This control system can adjust 
blood flow, blood vessel dilation, or oxygen extraction fraction to maintain a life-sustaining level of O2. 
When cells are suddenly deprived of sufficient O2 to maintain oxidative phosphorylation, the cells die 
either by necrosis or programmed cell death, apoptosis. This phenomenon is called hypoxia and it 
happens, for example, in stroke, myocardial infarction, or as a consequence of poor perfusion in diabetic 
limbs or arthritic joints. Cancer cells often respond to hypoxia in a different way – the fact that hypoxic 
tumors are up to three times more resistant towards radiation therapy than normoxic cells was observed 
by Gray over 50 years ago. 
Most of oxygen-breathing species express the highly-conserved transcriptional complex HIF-1 (Hypoxia-
inducible factor 1). The HIF signaling cascade mediates the effects of hypoxia on the cell. HIF-1, when 
stabilized by hypoxic conditions, regulates several genes to promote survival in low-oxygen conditions. 
These include glycolysis enzymes, which allow adenosine triphosphate (ATP) synthesis in an oxygen-
independent manner. Hypoxia often keeps cells from differentiating. However, hypoxia promotes the 
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formation of blood vessels, and is important for the formation of a vascular system in embryos, and 
cancer tumors
118
. 
Tumor cells are gradually exposed to chronic hypoxia as they outgrow their vascular supply, and this can 
lead to an adaptation that has a negative effect on their response to treatment. If the tumor is not well 
perfused, chemotherapeutic drugs do not have good access to each tumor cell. Furthermore, tumor cells 
rapidly adapt to hypoxia by slowing their growth rate, and conventional chemotherapy generally is toxic to 
cells at a level that is proportional to proliferation. Most chemotherapeutic drugs are essentially 
antiproliferation agents rather than specific anticancer agents so that when cells enter a resting phase in 
their cycle, they are not sensitive to these cytotoxic agents. 
Tumor hypoxia is a key mechanism that leads to resistance of treatment. Different invasive and 
noninvasive approaches have been developed for measuring tumor oxygenation, from oxygen-sensitive 
electrodes to hypoxia marker techniques using various labels/markers. These labels can be detected by 
different methods - autoradiography and immunohistochemistry, MRI, SPECT and the most advanced - 
PET. PET method seems to be an excellent solution for imaging hypoxia because it is non-invasive, 
quantitative, has high spatial resolution, and high sensitivity
119,120
. 
3.1.2 [18F]FMISO as a hypoxia tracer and its mechanism of action 
When chemists started developing hypoxia imaging strategies, the goal to identify three factors in cancer 
biology that were thought to limit response to treatment: decreased blood flow and hence delivery of 
drugs, decreased proliferation and hence fewer cycling cells, and absence of the oxygen enhancement 
ratio (OER) in these tumors
121
. 
The ideal noninvasive hypoxic marker should be: 
- specific for hypoxia 
- be structurally simple, non-toxic, easy to synthesize and allow repeated measurements 
- lipophilic to get an equal biodistribution in all tissues 
- hydrophilic at the same time to have a faster elimination 
- be sensitive at pO2 levels relevant to tumor therapy 
- offer the ability to quantify measurements and the difference between hypoxic and necrotic 
tissues 
 
Scheme 46. Hypoxia imaging PET radiopharmaceuticals [
18
F]FMISO, [
18
F]FAZA and 
64
Cu-ATSM. 
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18
F-labeled misonidazole, or [
18
F]FMISO, was the first hypoxia radiotracer proposed and has been the 
most extensively investigated one to date. Today [
18
F]FMISO is the most popular hypoxia marker for 
investigating tumor hypoxia with PET. Studies using [
18
F]FMISO demonstrated variable, but significant 
levels of hypoxia in several tumor types. [
18
F]FMISO PET imaging has been used as a prognostic 
indicator
122
. With a diagnostic tool as provided by hypoxia PET tracer [
18
F]FMISO the particular tissue 
situation becomes detectable, and, thus treatable. Although the clinical importance of hypoxia is obviously 
great both the clinical and scientific community has not been focusing much research activities on the 
hypoxia problem. 
[
18
F]FMISO is an azomycin-based hypoxic cell sensitizer that has a nearly ideal octanol:water partition 
coefficient (0.41) and, when reduced by hypoxia, binds covalently to cellular molecules at rates that are 
inversely proportional to intracellular oxygen concentration, rather than by any downstream biochemical 
interactions. 
 
Scheme 47. A schematic model of the reductive metabolism of [
18
F]FMISO in cells
123
. 
The covalent binding of nitroimidazoles is due to bioreductive alkylation based on reduction of the NO2-
group through a series of one‐electron steps in the absence of oxygen. The NO2-reduction is performed 
by nitroreductase enzymes, which are expected to show chiral specificity. It is conceivable that the 
reduction rates depend on chirality of the substrate. 
The 2‐electron reduction product hydroxilamine, bind stably in cells to macromolecules such as DNA, 
RNA, and proteins. In the presence of oxygen, a futile cycle results in which the first 1‐electron reduction 
product, the nitro radical anion, is re‐oxidized to the parent nitroimidazole, with simultaneous production 
of an oxygen radical anion. 
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Scheme 48. A simplified kinetic model of FMISO cellular bioreduction
123
. 
FMISO is not trapped in necrotic tissue because mitochondrial electron transport is absent. The normal 
route of elimination for FMISO is renal. A small fraction of [
18
F]FMISO is glucuronidated and excreted 
through the kidneys as the conjugate
124
. 
3.1.3 [18F]FMISO labelling strategies 
 
Scheme 49. Direct labelling strategies with nucleophilic fluoride
125
. 
A number of synthetic approaches were used for [
18
F]FMISO synthesis. The bis-tosylate was employed 
with the expectation that selective substitution of the primary OTs-group would be favored, with 
concomitant protection of the secondary alcohol function (Scheme 49). Labelled fluorine incorporation 
proceeded well (10-35%) within 30 minutes, but unfortunately the remaining OTs-group could not be 
cleaved to give [
18
F]FMISO. This work had, however, set the stage for the high yielding [
18
F]FMISO 
synthesis using tosylate-tetrahydropyranyl protection. 
The bromo-ketone was also examined with a proposed fluoro for bromo exchange, followed by a fast 
ketone reduction (Scheme 49, right). The fact that the bromo-ketone decomposed on a contact with TBAF 
without fluorine incorporation, led to abandoning this route. This result may reflect the acidity (enolization) 
in basic media. 
[
18
F]FMISO was first successfully prepared by Jerabek et al
126
, this method was based on the nucleophilic 
ring opening of the strained ring of epoxide using [
18
F]TBAF. 
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Scheme 50. 
This labelling reaction was intended to be a one-pot process that did not also rely on the additional 
removal of protecting groups to finish the synthesis, although the synthesis time was reasonable (1h) but 
the yield was too low (less than 1%) to develop the process for potential routine studies/production. The 
specific activity was limited to 100 GBq/mmol. 
The failure of the synthesis likely stems from the lack of a suitable activator (Lewis acid, e.g. H+ or metal 
cation) coordinated to the epoxide oxygen atom during nucleophilic fluoride displacement of the terminal 
C-O epoxide bond 
 
Scheme 51. 
The first useful two-step alternative synthesis of [
18
F]FMISO was developed
127
 demonstrating a high yield 
(RCY 40% from end of bombardment (EOB)) and purity with SA of 37 TBq mmol
-1
. The first step involves 
the synthesis of fluoroalkylating agent [
18
F]epifluorohydrin, which subsequently reacts with 2-
nitroimidazole to yield [
18
F]FMISO (Scheme 51). HPLC purification is needed to obtain high radiochemical 
purity. Further modifications have been reported with increasing labeling yields
128
, microwave heating
129
, 
SepPack cartridges
130
. 
Entry Reaction procedure RCY Overal 
synthesis 
time 
SA 
(if 
available
) 
Reference/ 
author 
1 
 
Nucleophilic attack of CA fluoride as TBAF 
on the epoxide ring of MISO-epoxide 
< 1% - - Jerabek
126
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2 
 
Nucleophilic attack of CA fluoride on the 
epoxide ring of MISO-epoxide 
< 1% 60 min 2.75 
Ci/mmol 
Jerabek
77
 
3 
 
Preparation of Epi-
18
F, distillation, coupling 
to 2-nitroimidazole under basic conditions 
(proton sponge) 
5% >40 min - Grierson
131
 
4 
 
Preparation of Epi-
18
F, distillation, coupling 
to 2-nitroimidazole under basic conditions 
40% 133 min 670 
Ci/mmol 
Grierson
131
 
5 
 
Preparation of Epi-
18
F from glycidyltosylate 
15-26% 120 min - Hwang
132
 
6 
 
Nucleophilic attack of CA fluoride on the 
epoxide ring of MISO-epoxide 
 
 
Preparation of Epi-
18
F from glycidyltosylate 
and glycidyltriflate, silica column 
purification, coupling to 2-nitroimidazole 
under basic conditions 
< 1% 
 
 
 
 
 
 
12-21% 
90 min 
 
 
 
 
 
 
90 min 
 
 
 
 
 
 
 
>400 
Ci/mmol 
Hwang
133
 
7 
 
18
F-fluoride nucleophilic substitution of 
tosylate on the THP protected precursor, 
hydrolysis 
45% 50 min - Lim
134
 
8 
 
Preparation of Epi-
18
F from glycidyltosylate, 
coupling to 2-nitroimidazole under basic 
62% 70 min - McCarthy
129
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conditions, microwave heating 
9 
 
18
F-fluoride nucleophilic substitution of 
tosylate on the THP-protected precursor, 
hydrolysis 
55-89% 15-50 min >600 
Ci/mmol 
Lim
135
 
10 
 
18
F-fluoride nucleophilic substitution of 
tosylate on the acetyl protected precursor 
12-18% 60-70 min - Cherif
136
 
11 
 
Preparation of Epi-
18
F from glycidyltosylate 
in a one-pot reaction procedure 
20% 80 min - Tada
137
 
Table 16. Synthetic approaches to [
18
F]FMISO
125
. 
Nucleophilic opening of MISO-epoxides could be performed as enantioselective reaction (table 16, entries 
1, 2 and 6), but because of low yields this route was abandoned. [
18
F]-epifluorohydrine two step labelling 
strategy can be used for the synthesis of enantiopure [
18
F]FMISO (Table 16, entries 3, 4, 5, 8, 11), 
however this method was too complicated for routine production and is no longer in use. 
The most practical method is based on the nucleophilic substitution of the tosylate leaving group by 
18
F-
fluoride on the tetrahydropyranyl protected precursor 1-(2’-nitro-1’-imidazolyl)-2-O-tetrahydropyranyl-3-O-
toluenesulfonylpropanediol (NITTP), followed by the hydrolysis of the protecting group (entries 7, 9). An 
automated synthesis of [
18
F]FMISO by this method using either HPLC or SepPaks for the purification of 
the radiotracer was also reported
138
. The radiochemical yield obtained when using NITTP was found to be 
higher than 40%, and reproducible, with a radiochemical purity > 97% and SA 34TBq mmol
-1
. The total 
synthesis time was 50 min. 
MISO-diol with leaving group (OTs, OTf, OMs) and hydroxyl protecting group (Ac or THP) usually gave 
high yields, but on the other hand stretches the time of synthesis (entries 7, 9, 10). Complicated multistep 
precursor synthetic route makes the synthesis more expensive. Enantiopure product cannot be obtained 
from this methodology. 
The question if R and S isomers give equal or different biodistribution in the organism – still needs to be 
answered. Our studies on the chiral synthesis of [
18
F]FMISO and in vivo studies of enantiopure samples 
of [
18
F]FMISO provide the answer to this question. 
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3.2 Results and discussion 
3.2.1 Discussions of [18F]FMISO synthesis 
Encouraged by the good results from radiofluorination of meso-epoxides (RCY up to 93% and ee 45% for 
cyclohexylfluorohydrine) we turned our attention to radiosynthesis of [
18
F]FMISO. 
[
18
F]FMISO, a 2-nitroimidazole 
18
F-fluorohydrine, is currently the most widely used tumor hypoxia PET 
imaging agent
139
. The direct 
18
F-hydrofluorination of epoxides is a particularly attractive approach. The 
one step enantioselective synthesis of non-radioactive FMISO was showcased by Doyle
97
. 
In our hands, the radiofluorination of the racemic F-MISO epoxide, obtained from 2-nitroimidazole and the 
racemic epichlorohydrin yielded [
18
F]FMISO in 17% RCY at room temperature. At 75 
o
C the RCY 
increased to 81% and the product was obtained in 38% ee. Lowering the reaction temperature to 50 
o
C 
proved to be a compromise reaction temperature: [
18
F]FMISO was obtained in 81% RCY and 55% 
enantiomeric excess (Scheme 52). 
 
Scheme 52. 
High boiling point of tAmOH gave us an opportunity to use a standard 10 ml disposable glass vial instead 
of a high pressure glass test tubes. Reaction time was reduced from 1 h (used in radiofluorination of 
meso-epoxides) to 10 min. MISO-epoxide seems to be more reactive than the meso-epoxides described 
above. Even heating to 50 
o
C is enough to get a high yield. 
Entry t, °C RCC, % ee, % 
1 25 17  
2 50 81 55 
3 75 81 38 
4 100 87 33 
Table 17. RCC and ee for [
18
F]FMISO at different temperatures. 
The reaction mixture volume should be minimized to achieve high conversion and simplify the purification 
procedure. We found the optimal volume is in the range of 1 ml. 
The decrease in catalyst loading (from 0.1 to 0.25 eq.) was effective; the same time was required to 
achieve the equal level of product formation. Surprisingly, further decrease of the catalyst amount (1:1 
and 2:1 catalyst – epoxide ratio) gave less conversion of 
18
F (Figure 21). 
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Figure 21. RCC to the Co(Salen)/MISO-epoxide ratio plot (10 min at 50 
o
C, 1 mL of tAmOH, conversion 
was determined by radio TLC). 
 
3.2.2 [18F]FMISO stereochemistry 
To determine the stereochemistry of [
18
F]FMISO we have also synthesized the enantiomerically pure cold 
FMISO to be used as a reference material. Our attempts to make direct fluorination (described above for 
meso-epoxides) were inefficient (Scheme 53, A). We used different route – first opening the epoxide in 
epichlorohydrin followed by alkylation of 2-nitroimidazole (Scheme 53, B): 
 
Scheme 53. 
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[Co(salen)]/[MISO-epoxide] 
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(S)-FMISO and (R)-FMISO isomers were also synthesized independently applying Doyle’s protocol to 
enantiopure substrates: 
 
Scheme 54. 
The comparison of chiral HPLC traces/radiotraces and TLC/radioTLC traces was done. The 
stereochemistry of these traces was in agreement with chiral traces of (S) and (R)-FMISO, synthesized 
from enantiomerically pure (R) and (S)- epichlorohydrines.  
The major enantiomer of [
18
F]FMISO from the reaction mediated with (R,R)-catalyst (Scheme 52, Scheme 
55) was identified as the (S)-stereoisomer - this result is in line with the (S)-stereochemistry for FMISO 
reported by Doyle: 
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Scheme 55. 
 
3.2.3 New strategy 
Unfortunately this approach (kinetic resolution) gave too low enantiomeric purity of [
18
F]FMISO for in vivo 
experiments (ee 55% at 50 
o
C). In the drug studies it is preferable to use pure compounds with as few 
impurities as possible. To gain information about an interaction of enantiomers, mixtures should be 
avoided. Often only one isomer is therapeutically active, but this does not mean that the other is really 
inactive. It may also contribute to the side-effect. The presence of a 50% impurity of isomeric ballast in 
drug, even if found to be innocent, should be avoided if it is possible
140
. 
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Entry Chiral HPLC trace Description 
1 
 
Racemic FMISO 
 
(UV trace (254 nm, 220-600 nm)) 
2 
 
 
(radiotrace) 
 
3 
 
 
(radiotrace) 
 
Table 18. Chiral HPLC trace and radiotraces from [
18
F]FMISO kinetic resolution. 
 
Therefore, another strategy to synthesize enentiomericaly pure FMISO was chosen - we decided to use 
enantiopure substrates (>99% ee) for further radiofluorination, instead of performing kinetic resolution of 
racemic substrates – MISO-epoxides. 
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Scheme 56. 
Synthesis of enantiopure substrates was done according to the procedure described below. The S and R 
epichlorohydrines (>99% ee) are commercially available compounds, what makes the chiral MISO-
epoxides more accessible. 
Due to the high activity, the radio synthesis was automated, using the LabVIEW controlled platform, 
equipped with the standard blocks and parts for a radiosynthesis (syringe pumps, valves, heaters/coolers, 
argon, helium and vacuum supply, and Geiger Muller counters). 
Figure 22. Automated radiosynthesizer. 
Overall, the radiosynthesis went as planned, producing the corresponding [
18
F]FMISO enantiomers in 
90% RCC and > 99% enantiopurity (Table 19). 
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Entry Chiral HPLC trace Description 
1 
 
Racemic FMISO 
 
(UV trace (254, 220-600 nm)) 
2 
 
 
>99% ee, radiotrace 
 
3 
 
 
>99% ee, radiotrace 
 
Table 19. Chiral HPLC – radio-HPLC traces of [
18
F]FMISO. 
 
3.2.4 Purification 
[
18
F]FMISO as any radiopharmaceutical requires careful purification before it can be released for 
biological studies or to a patient
141
. The main disadvantage of most modern methods for [
18
F]FMISO 
synthesis is purification using HPLC systems. This also affects the total synthesis time
142
. We have 
developed a new and efficient purification method which uses a simple solid phase extraction (SPE) 
methodology which does not require HPLC.  
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According to the developed protocol
†
, the reaction mixture was loaded onto the Supelco silica cartridge 
and sequentially washed with hexane and CH2Cl2 (Figure 23). This step removed tAmOH, HFIP and the 
Co(salen) catalyst, while the product, unreacted epoxide and unreacted 
18
F-fluoride remained on the 
cartridge. The cartridge was then gradient-eluted with CH2Cl2-MeCN mixture (0 - 33 % MeCN), which 
removed the unreacted epoxide and finally elutes [
18
F]FMISO into the collecting vial. The enantiomericaly 
pure [
18
F]FMISO, which was >99% radiopure (from radio-TLC and radio-HPLC traces) and contained no 
cold impurities (HPLC and GC control) after removing of solvents (evaporation under 100 mbar vacuum 
and low argon flow) was dissolved in saline and was filtered through a sterile filter to make the final 
[
18
F]FMISO formulation. 
 
Figure 23. [
18
F]FMISO purification scheme. 
                                                          
†
The protocol was made by F. Zhuravlev 
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The specific activity of [
18
F]FMISO was measured to be higher than 100 Gb/mmol. The purification takes 
40 min and the overall radiosynthesis time, including [
18
F]HF generation and transfer, is one hour. 
This [
18
F]FMISO purification scheme was adopted for the automated radiosynthesizer installed in our 
laboratory and rebuilt according to our needs. 
 
Figure 24. Radiosynthesizer adopted for [
18
F]FMISO synthesis. 
A program for handling the synthesis was written (LabVIEW platform): 
 
Figure 25. [
18
F]FMISO synthesizer program. 
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3.2.5 QC control 
The radiochemical identity was confirmed by HPLC/radio-HPLC and TLC/radioTLC methods. HPLC 
traces of the reference material and test solution were identical. TLC plates also showed same Rf for the 
reference and test samples. 
Table 20. C18 HPLC traces. 
Entry HPLC trace Description 
1 
 
Radio HPLC 
trace of a final 
product 
2 
 
UV HPLC trace 
of a final product 
 
Table 21. Chiral traces normal phase column. 
Entry Chiral HPLC trace Description 
1 
 
Racemic FMISO 
(reference 
standard from ABX 
advanced 
biochemical 
compounds), 0% ee 
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2 
 
Radiotrace of  
(S)-[
18
F]FMISO 
3 
 
UV trace of  
(S)-[
18
F]FMISO 
The content of residual solvents (MeCN and CH2Cl2) was checked with GC (under the constant oven 
temperature, flame ionization detection) and found to be below recommended values for [
18
F]FDG. Also, 
the mass of the vials was measured before and after evaporation of the solvent, the difference was less 
than 0.1 mg. The pH values were about physiological pH. 
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3.3 Experimental part 
 
2-Aminoimidazole-hemisulfate 
 
Scheme 57. 
2-Aminoimidazole-hemisulfate was prepared from O-methyl-isourea-hemisulfate and 2-amino-
acetaldehyde-diethylacetale according to the described procedure
143
. The title compound was isolated as 
an off-white solid (82%). 
1
H NMR data agreed with literature values
143
 
2-Nitroimidazole 
2-Nitroimidazole was prepared according to the modified method
144
 from 2-amino-imidazole-hemisulfate: 
 
Scheme 58. 
2-Aminoimidazole-hemisulfate (1.58 g, 12.0 mmol) was dissolved in water (20 mL) and fluoroboric acid 
(50% w/v, 14 mL). The solution was cooled to -20 °, and a solution of sodium nitrite (8.28 g, 119.2 mmol) 
in water (20 mL) was added dropwise. The solution was stirred at -10 °C for 30 min, then poured into a 
solution of CuSO4 (40 g, 238 mmol) in water (400 mL). Additional sodium nitrite (8.28 g, 119.2 mmol) was 
added and the mixture was stirred at room temperature for 2 h. The solution was extracted with EtOAc 
(400 mL) in a continuous extractor for 2 days. The organic extract was evaporated in vacuo, and the 
residue was recrystallized from ethanol to afford 2-nitroimidazole as a yellow powder (0.7 g, 52%). NMR 
data were in agreement with literature values
144
. 
Racemic 2-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole (MISO-epoxide) 
MISO-epoxide was prepared according to the modified procedure
145
 as a one pot synthesis: 
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Scheme 59. 
2-Nitroimidazole (1.00 g, 8.8 mmol, 1.0 eq.) and potassium carbonate (122 mg, 0.88 mmol, 0.1 eq.) was 
treated with (S)-epichlorohydrin (10 ml, 0.13 mol, excess), and the resultant mixture was gently heated 
and refluxed for 1 h under inert atmosphere. The hot solution was filtered through a glass filter; solvent 
was removed in vacuo and off-white precipitate was dried. EtOAc (20 mL) and 10 % NaOH (20 mL) were 
added to this precipitate and stirred for 1 h at room temperature. The organic layer was separated and 
dried over Na2SO4. Solvent was removed in vacuo and the remaining brown oil was passed through a 
silica cartridge with EtOAc (50 ml). Storing this yellow viscous liquid at -20 
o
C over night gave solid 
crystalline product (1.37 g, 92% yield, m.p. 50-60 
o
C). Spectral data agreed with literature values
145
. 
(S)-2-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole ((S)-MISO-epoxide) 
 
Scheme 60. 
A stirred suspension of 2-nitroimidazole (1.00 g, 8.8 mmol, 1.0 eq) and cesium carbonate (145 mg, 0.44 
mmol, 0.05 eq.) in 20 mL of dry EtOH was treated with (S)-epichlorohydrin (760 μl, 9.6 mmol, 1.1 eq.), 
and the resultant mixture was gently refluxed for 1 h under argon. The hot solution was filtered through 
glass wool; solids were washed with hot ethanol (10 mL). Half of the solvent was removed in vacuo, the 
concentrated solution was stored at -20 °C overnight. Off-white precipitate of 1-(2-Hydroxy-3-
chloropropyl)-2-nitroimidazole was filtered and dried in vacuo. A flask with solid chlorohydrine was 
charged with EtOAc (20 mL) and 10 % NaOH (20 mL) and stirred for 1 h at room temperature. The 
organic layer was separated and dried over Na2SO4. The solvent was removed in vacuo. Yield 88% (1.31 
g). 
(R)-MISO-epoxide was synthesized in analogues manner to (S)-MISO-epoxide from (S)-epichlorohydrin. 
Yield 85% (1.26 g) 
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Scheme 61. 
1-Chloro-3-fluoropropan-2-ol Epichlorohydrine (1.0 g, 10.8 mmol, 1.0 eq.) was reacted with TREAT HF 
(1.77 mL, 10.8 mmol, 1.0 eq.) in a sealed test tube for 2 h at 130 °C. After this time the ampule was 
opened and the reaction mixture was crashed with a mixture of ice (10 g) and ammonia hydroxide 
solution (30%, 10 mL), then washed with Et2O (3x15 mL). The organic phase was washed with aqueous 
HCl (1 N, 10 mL), and dried over Na2SO4. Removing of solvent and distillation of residues in kugelrohr 
(10 mbar, 90 °C) gave the desired chlorofluorohydrine in 88% yield (1.07 g). 
FMISO reference material Dry DMF (5 mL) was added to a mixture of 2-nitroimidazole (500 mg 4.4 
mmol, 1.0 eq.) and KO
t
Bu (490 mg 4.4 mmol, 1.0 eq.) with stirring. The reaction mixture was heated to 
130 °C for 15 min, afterwhich the mixture was cooled to 80 °C and potassium iodide (1 mg, <0.01 eq.) 
with 1-chloro-3-fluoropropan-2-ol (680 mg, 5.9 mmol, 1.3 eq.) was added. The mixture was stirred for 1 h 
at 130 °C. The solvent was then evaporated. The obtained solid was purified by column chromatography, 
using EtOAc/CHCl3 gradient(70/30 to 100) to afford pure FMISO as an off-white solid (80%, 505 mg) 
Radiofluorination of MISO-epoxide 
 
Scheme 62. 
A 10 mL glass reaction vial was charged with (R,R)Co(salen) (4.5 mg, 0.25 equiv., 0.0075 mmol ) and 
HFIP (250 ml). The resulting slurry was stirred for 5 min under air followed by the addition of MISO-
epoxide (5.0 mg, 1.0 equiv., 0.030 mmol) and the solution of [
18
F]HF·(-)tetramisole (0.6 mg, , 0.003 mmol, 
0.1 eq.) in tAmOH (3 mL). The reaction vial was heated to 50–65 
o
C. After 10 min the vial was opened 
and the reaction mixture was analyzed and purified as described further down. 
Purification of [
18
F]FMISO 
The reaction mixture (1 mL solution in tAmOH) was loaded onto Supelco (irreg. SiO2,40-60 um, 4 g)silica 
cartridge, preconditioned with hexane. The cartridge was washed with hexane (20 ml), CH2Cl2 (20 ml), 
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and CH2Cl2 / MeCN 3:1 (20 ml). Another portion of CH2Cl2 / MeCN 3:1 (20 ml) was collected and the 
solvent was removed with a flow of argon under vacuo. The residue was dissolved in 3 ml of sterile saline 
solution for injections and filtered through a sterile filter (0.22 um). 
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Chiral HPLC traces 
Chiral HPLC/radioHPLC was done using Chiralpak AD-3, 150 mm × 2.1 mm column using hexane-iPrOH 
(10% iPrOH volume) isocratic elution (flow rate 0.150 ml/min) 
 
Racemic FMISO (reference standard), 0% ee 
HPLC-UV trace (254 nm, 220-600 nm) 
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>99% ee, HPLC radiotrace 
 
 
HPLC-UV trace 
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>99% ee, HPLC radiotrace 
 
 
HPLC-UV trace 
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MISO-epoxide (reference) 
 
 
 
(-)-tetramisole (reference) 
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Purity tests 
(normal SiO2 plates, CHCl3-CH3CN 3:7) 
(R)-[
18
F]FMISO 
 
Substance R/F %Area 
Reg #1 0.01 0.08 
Reg #2 0.38 99.92 
 
(S)-[
18
F]FMISO 
 
Substance R/F %Area 
Reg #1 0.00 0.34 
Reg #2 0.35 99.66 
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(R)-[
18
F]FMISO 
HPLC radiotrace 
 
HPLC-UV trace 
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(S)-[
18
F]FMISO 
HPLC radiotrace 
 
HPLC-UV trace 
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3.4 In vivo studies 
Preliminary studies 
The in vivo studies were performed by our collaborators from the Panum institute – Dr. Jesper Tranekjær 
Jørgensen from the group of Prof. Andreas Kjaer. 
Two separate studies were performed in one .The mice were divided into two groups, 5 mice in each 
group (mouse average mass 26.2 g) with two FaDu tumors (average size 489 mm
3
, in range from 65 mm
3
 
to 1080 mm
3
) were injected with R and S [
18
F]FMISO solutions (4.91±0.55 MBq ((R)-[
18
F]FMISO) and 
4.55±077 MBq ((S)-[
18
F]FMISO)) made in our group. After a waiting period (1.5 h and 4 h after injection, 
instead of preferred 1 h and 3 h) the distribution of [
18
F]FMISO in the mice was measured via a PET 
scanner. This timing is important to ensure that the tracer has equilibrated proportionally to the partition 
coefficient in blood and tissue
121
. 
 
Figure 2613. 
The counts were corrected for decay, counting efficiency, tissue weight and injected dose. Regions of 
interest were drawn on all scans on tumors, sections of muscle and liver tissue and %ID/g, tumor-to-
muscle (T/M) and tumor-to-liver (T/L) ratios calculated. 
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Figure 27. 
Due to some technical problems with the PET-CT scanner, the time between injection and scan was 
different for the R and S isomer (average time for S injected 83.8 min (from 63 to 100 min) and 93.4 for 
the R-injected (from 88 to 99 min)) 
This scan showed a slightly higher tumor uptake for the R-form, also a higher uptake was observed in 
muscles. Tumor-to-muscle ratio, however, was higher for the S-form. 
The second scan (S-form average time 271.8 min (from 256 to 291 min), the R-form average time 286.8 
min (from 278 to 293 min)) also showed a higher tumor uptake for R-isomer, while almost no difference 
between liver and muscles uptakes was observed. 
Because of the PET-CT instrument problems resulted in scattered time between injection and scans, we 
used this data set as the preliminary observations. Also, the dispersion in tumor size was immense – from 
65 to 1080 mm
3
. Big tumors showed an absence of [
18
F]FMISO in the center of the tumor – this will lead 
to incorrect %ID/g numbers 
 
Figure 28. The cross section showing different action of big (left) and small (right) tumors – no radiotracer 
in the center of the left tumor was observed. 
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Figure 29. 
The well counter data showed more or less the same situation with distribution of [
18
F]FMISO in different 
tissues. As a conclusion we can say that the behavior of these two isomers seems to be almost the same. 
Second set 
Our second attempt was done more accurately – the difference of periods between injection and scans 
was minimal (63.0±6.2 min and 183.4±3.8 min), also tumors were more or less equal in size, [
18
F]FMISO 
was distributed evenly in a tumor. 
 
Figure 30. 
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Figure 31. 
PET-CT tracer uptake of the two stereoisomers showed no significant difference between the R and the 
S-form of [
18
F]FMISO 
 
Figure 32. 
The well counter data shows more or less the same distribution as the PET-scans data. 
Dynamic PET scans 
For the dynamic FMISO scans another set of the experiment was performed. Two groups of mice, three 
in each group were PET scanned for 2 hours; acquisition was started 12-20 seconds before the mice 
were injected with [
18
F]FMISO solutions. 
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Figure 33. 
In most of the tissues there are no differences between the time activity curves (TACs) of the R- and the 
S-form, but in the tumor and muscle tissues there appears to be a tendency that the early uptake of the 
R-form is higher than the S-form (Figure 33). The difference decreases over the experiment and as the 
increased uptake applies for both tumor and muscle tissue there are no difference in tumor-to-muscle 
ratio. Some kind of difference between the two enantiomers could be observed, but it is negligible. 
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Conclusions 
In the presented work the enantioselective Co(salen)-mediated no-carrier-added radiofluorination of 
epoxides has been achieved for the first time. The procedure employs [
18
F]HFgas, as an efficient source of 
nucleophilic 
18
F-fluoride. 
A number of model meso-epoxides were successfully radiofluorinated producing 
18
F-fluorohidrines in high 
RCC and RCY, and modest enantioselectivity. The developed procedure is simple, rapid and leads itself 
to easy automation. 
This methodology was adopted for the first automated enantioselective single step radiosynthesis of PET 
hypoxia radiotracer [
18
F]FMISO in 81% RCY and 55% enantioselectivity. The use of enantiopure 
substrates for the synthesis of both enantiomers allowed us to obtain the (S) and (R)-[
18
F]FMISO 
enantiomers with > 99% enantiopurity. 
Quantitative and pharmacokinetic data were obtained for the first time for the both enantiomers of 
[
18
F]FMISO. The R-form showed higher uptake in tumor as well as in muscle tissues, thus displaying 
nearly identical tumor-to muscle ratios and showing very similar imaging properties of both the (S) and 
(R)-[
18
F]FMISO. 
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 Appendix 
Co(salen)-mediated enantioselective radioﬂuorination of epoxides.
Radiosynthesis of enantiomerically enriched [18F]F-MISO via
kinetic resolution
Evgeny Revunov, Fedor Zhuravlev *
Hevesy Laboratory, Center for Nuclear Technologies, Technical University of Denmark, Frederiksborgvej 399, Building 202, Roskilde, Denmark
1. Introduction
The radioisotope ﬂuorine-18, produced by the 18O(p,n)18F
reaction, undergoes positron decay (97% b+, 649 keV) with a half-
life of 109.7 min, making it possible to incorporate ﬂuorine-18 into
organic molecules via short radiosynthesis. Due to its low positron
energy the resulting 18F-labeled radiotracers typically yield excel-
lent PET (positron emission tomography) images with the spatial
resolution as high as 2 mm [1]. The favorable radioimaging
properties of ﬂuorine-18 are offset by its multi-step recovery and
activation process. The high speciﬁc activity radionuclide is typically
produced and extracted from water solution as potassium
[18F]ﬂuoridecryptand complex. As a result, radioﬂuorination is
dominated by nucleophilic substitution chemistry of [18F]ﬂuoride
[2,3]. In contrast, recent advances in transition metal mediated
ﬂuorination utilized a variety of ﬂuoride sources and metal systems
[4]. The substrate scope includes alkynes [5,6], alkyl- and allyl
halides [7–9], trichloroacetimidates [10], carbonates, p-nitrobenzo-
ates [9,11], aryl triﬂate [12], functionalized aryls [13–15], and
epoxides. In particular, transition metal-mediated asymmetric
hydroﬂuorination of epoxides, pioneered by Haufe [16–18] has
been recently developed into a highly efﬁcient catalytic system by
Doyle and co-workers [19,20]. However with few notable exceptions
[9,10,21], the translation of transition metal mediated19F-chemistry
into non carrier added (n.c.a.) 18F-radioﬂuorination so far has been
limited. Although the nucleophilic epoxide opening with [18F]ﬂuo-
ride has received attention over the years the efﬁcient reaction
remains challenging and the yields vary signiﬁcantly [22–25].
Recently reported entry into efﬁcient production of [18F]HF [26]
and the use of [18F]HFbase for radioﬂuorination [27] prompted us
to investigate the extension of Co(salen)-mediated enantioselec-
tive hydroﬂuorination of epoxides [19,20] to the corresponding
18F-hydroﬂuorination. Herein, we disclose the ﬁrst example of
n.c.a. enantioselective radioﬂuorination of epoxides and the kinetic
resolution of important PET tracer [18F]F-MISO using [18F]HF and
Co(salen)/chiral thiourea system under the n.c.a. radioﬂuorination
conditions.
2. Results and discussion
In a preliminary experiment, [18F]HF, produced by acidiﬁcation
of cyclotron-irradiated [18O]water and trapped as
[18F]()tetramisole hydroﬂuoride, was reacted with 9-oxabicy-
clo[6.1.0]non-4-ene 1 in the presence of chiral (R,R)-Co(salen) 2
and hexaﬂuoroisopropanol (HFIP) in tert-butyl methyl ether
(TBME) (Scheme 1).
After 1 h at 100 8C radio-TLC analysis indicated that the
corresponding 18F-ﬂuorohydrin 3 was obtained in 78% RCY. The
enantioselectivity was only 32%, as measured by the normal phase
chiral radio-HPLC performed on a Chiralpak AD-3 column.
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Lowering the reaction temperature to 75 8C led to an increase in
enantioselectivity to 48% but the RCY of 3 dropped to 25%. No
reaction was observed at room temperature. We have also noticed
that HFIP, used in the earlier work to facilitate the release of HF
from benzoyl ﬂuoride [19,20], was essential for successful radio-
ﬂuorination. A control experiment where [18F]HF was introduced
into the reaction mixture without HFIP yielded no 18F-ﬂuorohydrin
3 (Table 1, entry 2).
Other alcohols and phenols, varying in acidity and steric bulk
were markedly less effective than HFIP (Table 1, entries 3–7).
Although the role of hydroxylic additives is unclear at the moment,
there seemed to be a pronounced ‘‘ﬂuorous’’ effect, as the RCY
increased to various degrees when the ﬂuorinated analogs were
used (Table 1, entries 3 vs. 1, 4 vs. 5, and 6 vs. 7). To rule out the
carrier effect due to possible traces of cold ﬂuoride or HF in HFIP,
the latter was carefully puriﬁed by a sequential passing through
basic alumina and silica, followed by vacuum distillation. This
puriﬁcation had no discernible effect on either the RCY or the
speciﬁc activity of the product (Table 1, entry 10). The pKa of the
protic additives did not seem to play the major role in the
‘‘ﬂuorous’’ effect as phenol (pKa = 10) remained inferior to HFIP
(pKa = 9.3, Table 1, entries 1 and 6.) In our hands, the pre-oxidized
forms of the catalyst obtained either by using (salen)Co(III)OTs or
by tBuOOH oxidation of (salen)Co(II) [19] were ineffective in the
absence of HFIP. The effect of HFIP was also prominent under the
cold conditions: the freshly prepared (tetramisole)[19F]HF used in
combination with 2 gave the desired ﬂuorocyclohexanol in 95%
yield within 2 h. Without HFIP the reaction took two days to reach
the same level of conversion (Scheme 2). Based on these
observations we believe that HFIP kinetically facilitates hydro-
ﬂuorination by acting on one or more catalytic Co(salen) species.
Screening of a few nitrogen bases revealed that ()tetramisol
was the only effective base as other bases yielded no 18F-
hydroﬂuorination products (Table 1, entry 8). We have also
conﬁrmed the strong cooperative effect of Co(salen)/base on RCY
and enantioselectivity observed earlier [19,20]. The mismatched
enantiomer ent-(S,S)-2 gave the ent-3 in only 36% RCY and 27% ee.
Changing the solvent from TBME to 2-methyl-2-butanol (tAmOH)
resulted in lower yield but higher enantioselectivity (Table 1, entry
9).
The substrate scope of 18F-hydroﬂuorination was investigated
by reacting a substrate with a mixture of [18F]()tetramisole
hydroﬂuoride, (R,R)-Co(salen) 2, and HFIP in TBME at 100 8C
(Table 2). The RCYs for desymmetrization of the meso epoxides
were uniformly high (entries 1–3). However, the enantioselec-
tivities were only moderate-to-low, most likely due to high
reaction temperatures required for opening of cyclic epoxides. This
was consistent with the moderate 52% ee obtained after applying
the cold protocol to cyclopentane oxide. Surprisingly, terminal
polycyclic aromatic epoxides proved to be challenging substrates:
the 1-naphthalenyloxirane (entry 4) was unreactive, and 9-
anthryloxirane gave unidentiﬁed products.
Recognizing the general limitations imposed by the use of
normal phase chiral radio-HPLC (column availability/price, solvent
system), we sought a more practical alternative to measuring RCY
and ee. Gratifyingly, the diastereomeric derivatization of ﬂuor-
ohydrins as Boc-Ala or Boc-Val esters with the subsequent use of
radio-TLC provided for an inexpensive and expeditious quantiﬁ-
cation of RCY and de for all ﬂuorohydrins in this study.
Interestingly, the separation of diastereomeric esters was consis-
tently better on the C18-modiﬁed silica than on the regular silica,
chiral silica, or alumina oxide. In all cases the RCY and de obtained
with the radio-TLC were consistent with those obtained by the
radio-HPLC (Fig. 1, see the Supporting Information for more
details).
One important question which needed to be answered was
whether the ﬂuoro- and radioﬂuorohydrins resulting from the
(R,R)-Co(salen)-mediated opening of meso epoxides with PhCOF/
HFIP and [18F]HF had the same absolute conﬁguration. Because the
direct determination of absolute stereochemistry of radiolabeled
Scheme 1. Enantioselective 18F-hydroﬂuorination of 9-oxabicyclo[6.1.0]non-4-ene
using [18F]HF/()tetramisol-(R,R)-Co(salen).
Table 1
The results of enantioselective 18F-hydroﬂuorination as shown in Scheme 1.
Entrya Base R0OH Solvent RCYb [%] eec [%]
1 ()Tetramisole HFIP TBME 78 32
2 ()Tetramisole none TBME <1 –d
3 ()Tetramisole iPrOH TBME 3 –
4 ()Tetramisole tBuOH TBME 5 –
5 ()Tetramisole (CF3)3COH TBME 26 –
6 ()Tetramisole PhOH TBME 5 –
7 ()Tetramisole C6F5OH TBME 16 –
8 DBU, DBN, Et3N, Py HFIP TBME <1 –
9 ()Tetramisole HFIP tAmOH 50 68
10 ()Tetramisole HFIPe tAmOH 53 –
a All reactions were performed in duplicate, average values are given.
b RCY: analytical decay-corrected RCY were measured by radio-HPLC or radio-TLC and based on [18F]HF.
c Determined using radio-HPLC on a Chiralpak AD-3 column.
d Not measured.
e Puriﬁed (see text), SA > 100 Gb/mmol.
Scheme 2. The effect of HFIP on enantioselective 19/18F-hydroﬂuorination of
cyclohexene oxide using the [19/18F]HF/()tetramisol-(R,R)-Co(salen) system.
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substrates was not possible due to their subnanomolar concentra-
tions, we developed an indirect method, based on comparison of
18F-radioﬂuorohydrin derivatives with their 19F-isotopomers, for
which absolute conﬁguration could be reliably established. The
workﬂow is illustrated in Scheme 4. The (R,R)Co(salen)-mediated
ﬂuorination and radioﬂuorination of meso epoxides (A) yielded the
corresponding isotopomeric ﬂuorohydrins (B) and radioﬂuorohy-
drins (B0) having identical Rf values as measured by normal phase
chiral HPLC/radioHPLC. The reaction of (B) with (R)-()-a-
methoxy-a-(triﬂuoromethyl)phenylacetyl chloride was fast and
complete within minutes giving the corresponding Mosher esters
(C) in high diastereoselectivity (de > 95%). The 1H NMR based
Mosher analysis established the (S,S) conﬁguration of the major
diastereomer C (Table 3). The diastereomers C were resolvable by
the standard reverse-phase HPLC. The same Mosher derivatization
of the corresponding radioﬂuorohydrins (B0) resulted in radio-
HPLC-resolvable diastereomeric 18F-isotopomers C0. The C and C0
had identical HPLC/radioHPLC retention times, thus establishing
the (S,S) conﬁguration of [18F]2-ﬂuorocyclohexanol, [18F]8-ﬂuor-
ocyclooct-4-enol, and [18F]2-ﬂuoropentanol (Table 3).
Encouraged by good RCY and promising enantioselectivities of
the resulting 18F-ﬂuorohydrins we turned to radiosynthesis of
[18F]F-MISO. [18F]F-MISO, a 2-nitroimidazole 18F-ﬂuorohydrine, is
currently the most widely used tumor hypoxia PET imaging agent
[28]. Although alternative nitroimidazole radioﬂuorination pro-
cedures based on Si-18F and Al-18F chemistries were recently
reported [29,30], the direct 18F-hydroﬂuorination of epoxides is a
particularly attractive approach. The one step enantioselective
synthesis of non-radioactive F-MISO was recently showcased by
Doyle and Kalow [19]. In our hands, the radioﬂuorination of the
racemic F-MISO epoxide [31], obtained from 2-nitroimidazole and
the racemic epichlorohydrin yielded [18F]F-MISO in 17% RCY at
room temperature (Scheme 3). At 75 8C the RCY increased to 81%
and the product was obtained in 38% ee. Finally, 50 8C proved to be
the optimal reaction temperature: [18F]F-MISO was obtained in
81% RCY and 55% enantiomeric excess. To determine the absolute
conﬁguration of the major enantiomer the independent syntheses
of both the (S) and the (R)-F-MISO were undertaken (Scheme 5).
HPLC/radio-HPLC showed that the Rf value of the major
radioactive product was identical to that of the authentic (S)-F-
MISO establishing the conﬁguration of the major enantiomer of
[18F]F-MISO as the (S) stereoisomer. This result is in line with the
(S) stereochemistry reported by Kalow and Doyle [19].
Fig. 1. The diastereomeric derivatization of 3 and the corresponding radio-TLC trace.
Scheme 3. Enantioselective 18F-hydroﬂuorination of meso and terminal epoxides
(see Table 2).
Table 2
The results of enantioselective 18F-hydroﬂuorination as shown in Scheme 2.a
Entrya Epoxide Solvent RCYb [%] eec [%]
1 TBME or
t-AmOH
93 45
2 TBME 73 20
3 TBME 78 33
4 TBME <1 —
a 2, [18F]HF/()tetramisole, HFIP,100 8C, 1 h, average of 3 experiments.
b RCY: analytical decay-corrected RCY were measured by radio-HPLC or radio-
TLC and based on [18F]HF.
c Determined using radio-HPLC on a Chiralpak AD-3.
Scheme 4. Determination of absolute stereochemistry using Mosher esters.
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[18F]F-MISO is a radiopharmaceutical which requires careful
puriﬁcation before it can be released to the patient [32]. Currently,
[18F]F-MISO is puriﬁed using HPLC [33]. We have developed a new
and efﬁcient puriﬁcation method which uses a simple solid phase
extraction (SPE) methodology and does not require HPLC.
According to the developed protocol, the reaction mixture
(Fig. 2, top radio-TLC trace) is loaded onto the Supelco silica
cartridge and sequentially washed with hexane and CH2Cl2. This
removes tAmOH, HFIP and the Co(salen) catalyst, while the
unreacted [18F]ﬂuoride remains on the cartridge. The cartridge is
then gradient-eluted with CH2Cl2:MeCN, which removes the
epoxide and ﬁnally elutes [18F]F-MISO. The enantiomerically
enriched [18F]F-MISO, which is 99% radiopure and contains no
cold impurities is dissolved in a saline solution and is ﬁltered
through a sterile ﬁlter to make the ﬁnal [18F]F-MISO formulation.
The speciﬁc activity of [18F]F-MISO was measured to be higher than
100 Gb/mmol. The puriﬁcation takes 40 min and the overall
radiosynthesis time, including [18F]HF generation and transfer,
is 1.5 h.
Akin to the recently reviewed metal-mediated radioﬂuorina-
tions, [4] the Co(salen)-mediated radioﬂuorination does not
require a carrier nor does it form any other 18F-containing
byproducts. Given the same sense of enantiomeric induction and
generally comparable, albeit attenuated rates, it is tempting to
assume that radioﬂuorination and the parent ﬂuorination follow
the same mechanism [19]. However, different reactivity toward
terminal epoxides, different behavior with respect to the bases
(Table 1, entry 8) and the concentration argument (the sub-
nanomolar concentration of [18F]ﬂuoride should preclude the
formation of any dimeric metal-ﬂuorides), suggest that the
Fig. 2. Puriﬁcation of [18F]F-MISO ﬂowchart.
Table 3
Determination of absolute stereochemistry by 1H NMR using Mosher esters as shown in Scheme 4.
Entry Fluorohydrin Proton DdSR Carbon conﬁguration
1 2-Fluorocyclohexanol –FCH– 4.48–4.39 = 0.09 (pos.) S
–CH2–HCO– 1.34–1.48 = 0.14 (neg.)
2 8-Fluorocyclooct-4-enol –FCH– 4.78–4.70 = 0.08 (pos.) S
–CH2–HCO– 2.10–2.17 = 0.07 (neg.)
1.72–1.86 = 0.14 (neg.)
3 2-Fluoropentanol –FCH– 5.06–4.96 = 0.10 (pos.) S
–CH2–HCO– 2.18–2.21 = 0.03 (neg.)
1.63–1.79 = 0.13 (neg.)
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mechanistic differences between the tracer 18F and the bulk 19F
chemistries might be larger than initially expected.
3. Conclusions
In conclusion, we report here the ﬁrst example of transition
metal mediated enantioselective n.c.a. radioﬂuorination of epox-
ides. The procedure utilizes gaseous [18F]HF and requires elevated
temperature producing the 18F-ﬂuorohydrines in high RCY and
modest enantioselectivities. The use of this methodology allowed
us to accomplish the ﬁrst enantioselective, single step radio-
synthesis of [18F]F-MISO in 81% RCY and 55% enantioselectivity.
Animal studies directed at elucidating the impact of absolute
stereochemistry of [18F]F-MISO on hypoxic tumor PET imaging are
in progress.
4. Experimental
The epoxides (9-oxabicyclo[6.1.0]non-4-ene, cyclohexene ox-
ide and cyclopentene oxide), epichlohydrins ((S), (R) and racemic),
2-nitroimidazole, ()tetramisole hydrochloride were purchased
from Sigma–Aldrich and used as received without further
puriﬁcation. The solvents (tert-butyl methyl ether (TBME, anhy-
drous), and 2-methyl-2-butanol (tAmOH), anhydrous) were
purchased from Sigma–Aldrich and used as received without
further puriﬁcation. 1,1,1,3,3,3-Hexaﬂuoro-2-propanol (HFIP) was
purchased from Sigma–Aldrich and puriﬁed by sequential passing
through silica, activated alumina followed by vacuum distillation.
The reported RCYs refer to analytical radio-HPLC or radio-TLC
yields for meso-epoxides, and isolated yields for [18F]F-MISO; all
yields were based on [18F]HF/()tetramisole and decay corrected.
The speciﬁc activity was estimated from a 5 point-calibration curve
using UV-VIS spectroscopy. All reactions were performed without
exclusion of moisture and air. The radioﬂuorinations were
performed in the pressure glass tubes (ACE GLASS Inc.) equipped
with PTFE screw caps. The reaction vials used for radioﬂuorination
were washed with piranha solution (3:1 mixture of conc. H2SO4
and 30% H2O2) and oven-dried at 150 8C overnight. Radio-TLC was
performed using a Raytest MiniGita TLC scanner. Thin-layer
chromatography (TLC) was run on precoated plates of silica gel
60 F254 (Merck), chiral modiﬁed, impregnated with Cu2+ reagent,
chiral-silica gel matrix silica gel C18 on TLC Plates (Fluka) or
reverse phase C18-silica gel matrix TLC UniplatesTM (Analtech).
The Supelco silica cartridges (4 g) were purchased from Aldrich.
The HPLC and radio-HPLC measurements were performed on
Hitachi EliteChrom equipped with Carrol&Ramsey 105-S radio-
detector. The normal phase chiral HPLC/radio-HPLC was done
using Chiralpak AD-3, 150 mm  2.1 mm column using hexane-
iPrOH isocratic elution. The reverse phase HPLC was performed
on a Phenomenex Luna 3u C18(2) column (100 A, 100 mm 
2.00 mm) using ﬂow rate at 0.200 mL/min and isocratic elution
with 9/1 (5% ACN in H2O)/(100% ACN). The radiochemical purity
was determined by radio-TLC or radio-HPLC and calculated as:
RCP = (Areaproduct/Total area)*100%. The RCY (analytical) was
determined by the dose calibrator and calculated as RCY =
Activityproduct*RCP/Activity[18F]HF. The preparative RCY of [18F]F-
MISO was determined analogously on the cartridge-puriﬁed sterile
saline formulation of the product.
4.1. [18F]Fluoride
The aqueous solutions of [18F]ﬂuoride were prepared by the
18O(p,n)18F reaction in a GE PETtrace cyclotron using a 1.8-mL of
95% enriched [18O]water irradiated by a 14.1-MeV beam at 20–
25 mA for 60–90 min.
4.2. [18F]HF generation and transfer
[18F]Fluoride (cyclotron target wash, 1 mL, 150–7000 MBq) was
added to a polyethylene (PE) reaction vial containing H2SO4 (98%,
5 mL). The reaction vial was heated for 30 min at 80 8C in an
ultrasound bath while being irradiated at 35 kHz. [18F]HF was
carried through the PE tubing (ID = 3.0 mm, OD = 4.5 mm, Buch&-
Holm, Denmark) by argon ﬂow (300–400 scc/min) into a PE
receiving vial containing ()tetramisol (0.02 mmol) in TBME or
tAmOH (3 mL) at 0 8C. The [18F]HF yield was about 80% as
measured by the dose calibrator.
4.3. Radioﬂuorination of the meso- and terminal polycyclic aromatic
epoxides
An oven-dried high pressure glass tube equipped with a stir bar
was charged with Co(salen) 2 (or ent-2) (12.0 mg, 0.020 mmol)
and HFIP (112 mL, 0.80 mmol). The resulting slurry was then
stirred for 5 min under air; an epoxide (0.20 mmol) was added neat
followed by the solution of [18F]HF/()-tetramisole (4.1 mg,
0.020 mmol) in TBME (3 mL). The reaction mixture was then
heated at 100 8C for 1 h. The reaction conversion was monitored by
radio-TLC. No loss of activity due to volatilization was observed.
4.4. Derivatization of [18F]-ﬂuorohydrins with the
hydroxysuccinimide esters of Boc-protected amino acids
1 mL of the reaction mixture containing the corresponding 18F-
ﬂuorohydrin was placed into a 10 mL vial and the solvent was
evaporated with a ﬂow of argon. 1 mL of CH2Cl2 was then added
and the solution was evaporated to dryness again. The resulting
residues were dissolved in 1 mL of CH2Cl2. The second glass vial
was charged with Sc(OTf)3 (1 equiv., 0.04 mmol, 21 mg), DMAP
(5 equiv., 0.20 mmol, 26 mg) and 0.5 mL of CH2Cl2, this mixture
was stirred for 5 min at rt. Then, the solutions were combined and
the resulting mixture was stirred for additional 2 min at room
temperature, followed by the addition of Boc-Ala-OSu (5 equiv.,
0.21 mmol, 60 mg) in one portion, and the mixture was stirred
2 more minutes, providing the diastereomeric material for
radio-TLC.
4.5. Radiosyntesis of [18F]F-MISO
A glass reaction vial was charged with (R,R)Co(salen) (4.5 mg)
and HFIP (250 ml). The resulting slurry was stirred for 5 min under
air followed by the addition of MISO-epoxide (5.0 mg, 1.0 equiv.,
0.030 mmol) and the solution of [18F]HF-levamisole (0.6 mg,
0.1 equiv., 0.003 mmol) in t-AmOH (3 mL). The reaction vial was
Scheme 5. Enantioselective radiosynthesis of [18F]F-MISO via kinetic resolution and
the proof of absolute stereochemistry of the major enantiomer.
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heated at 50–65 8C. After 15 min the pressure tube was opened and
the reaction mixture was loaded onto a Supelco silica cartridge
preconditioned with hexane. The cartridge was washed with
hexane (20 mL), CH2Cl2 (20 mL), and eluted with CH2Cl2: MeCN
(3:1, 4 10 mL). The product was collected in two last fractions.
The solvent was removed with a ﬂow of Ar; the residue was
dissolved in 3 mL of DPBS buffer and ﬁltered through a 0.22 mm
sterile ﬁlter. The total time of the synthesis was 1 h. The
radiochemical purity of [18F]F-MISO was higher than 99%, and
the speciﬁc activity was found to be greater than 100 GBq/mmol.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jﬂuchem.2013.09.
006.
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(-)Tetramisole was prepared from (-)tetramisole hydrochloride according to the described 
method1 and recrystallized from Et2O. 
 
   
(R,R)-Co(salen) and (S,S)-Co(salen) were purchased from Strem Chemicals and recrystallized 
from hot TBME under argon. 
 
 
The racemic 1-(2,3-epoxypropyl)-2-nitroimidazole or MISO-epoxide were synthesized 
according to the literature procedure2. 
 
 
                                                     
1
 V. B. Birman, X. Li, Org. Lett. 2006, 8, 1351. 
2
 U.S. Pat. Appl. Publ. 20080102026, 01 May 2008. 
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(S)-MISO-epoxide and (R)-MISO-epoxide were prepared according  to the literature 
procedure3. 
 
 
 
The racemic fluorohydrins (8-fluorocyclooct-4-enol, 2-fluorocyclohexanol and 2-
fluorocyclopentanol) were synthesized in the same manner: a glass ampule was charged with 
an epoxide (18.4 mmol, 1.0 eq.) and TREAT HF (3.0 mL, 18.4 mmol, 1.0 eq.). The ampule was 
flame-sealed and heated overnight at 80 °C. The product was precipitated with a mixture of ice 
(10 g) and ammonia hydroxide  (30%, 10 mL), and washed with Et2O (3x20 mL). The organic 
phase was washed with HCl (1N, 10 mL) and dried over Na2SO4. The solvent was removed in 
vacuo, and the oily residues were passed through a short SiO2 column (EtOAc/Hexane, 1/5 to 
1/1) giving 80-90% of fluorohydrin as a single product4. 
 
 
The racemic 1-chloro-3-fluoropropan-2-ol was synthesized from the corresponding racemic 
epichlorohydrin using the method described above for the meso-epoxides. Epichlorohydrin (1.0 
g, 10.8 mmol, 1.0 eq.) was reacted with TREAT HF (1.77 mL, 10.8 mmol, 1.0 eq.) in a sealed 
ampule for 2 h at 130 °C. The ampule was opened and the product was precipitated with a 
mixture of ice (10 g) and ammonia hydroxide solution (30%, 10 mL), washed with Et2O (3x15 
mL). The organic phase was washed with HCl solution (1 N, 10 mL), and dried over Na2SO4. The 
reaction mixture was concentrated on a Rotovap and distilled using Kugelrohr apparatus (10 
mbar, 90 °C) giving the desired chlorofluorohydrin in 88% yield (1.07 g). The spectral data were 
in agreement with the literature5.  
                                                     
3
 H. Weinmann, M. Harre, K. Koenig, E. Merten, U. Tilstam, Tetrahedron Letters 2002, 43, 593–
595. 
4
 G. Alvernhe, A. Laurent, G. Haufe, J. Fluorine Chem. 1986, 34, 147‐156. 
5
 Patent: WO2012/98461 A1, 2012; Patent Family: WO2012/98461 A1. 
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(R)- and (S)-1-chloro-3-fluoropropan-2-ols were synthesized in a same manner from the (R)- 
and (S)-epichlorohydrins respectively, in 86% (1.03 g) and 83% (1.01 g) yields, respectively. 
 
F-MISO. Dry DMF (5 mL) was added to a mixture of 2-nitroimidazole (500 mg 4.4 mmol, 1.0 eq.) 
and KOtBu (490 mg 4.4 mmol, 1.0 eq.) with stirring. The reaction mixture was heated at 130 °C 
for 15 min, the mixture was cooled to 80 °C, and potassium iodide (1 mg, <0.01 eq.) and 1-
chloro-3-fluoropropan-2-ol (680mg, 5.9 mmol, 1.3 eq.) were added. The mixture was stirred for 
1 h at 130 °C. The solvent was evaporated off, and the product was purified by column 
chromatography, using EtOAc/CHCl3(70/30 to 100), to afford pure F-MISO as off-white solid 
(80%, 505 mg). The 1H NMR was in agreement with the literature6. 
 
The (S) and (R)-F-MISO were synthesized in a similar manner from (R) and (S)-epichlorohydrins 
and used as “cold” standards for radio-TLC. 
 
HF-(-)tetramisole was prepared analogously to  [18F]HF-(-)tetramisole  using 2 mL of HF (48 wt. 
% in H2O) and 8 mL of conc. H2SO4.  
 
Derivatization of [18F]-fluorohydrins with hydroxysuccinimide esters of Boc-protected amino 
acids. 1 mL of radiofluorination  reaction mixture was placed into a 10 mL vial and the solvent 
                                                     
6
 J. A. Kalow, A. G. Doyle, J. Am. Chem. Soc. 2011, 133, 16001–16012. 
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was evaporated with a flow of argon. 1 mL of CH2Cl2 was then added and evaporated again to 
dryness. The resulting  residue was redissolved in 1 mL of CH2Cl2. The second glass vial (4 mL 
vial with a screw top) was charged with Sc(OTf)3 (1 eq., 0.04 mmol, 21 mg), DMAP (5 eq., 0.20 
mmol, 26 mg) and 0.5 mL of CH2Cl2 and the mixture was stirred 5 min at rt. The solutions from 
the two vials were combined and the resulting mixture was stirred for additional 2 minutes at 
room temperature, followed by the addition of Boc-Ala-OSu (5 eq., 0.21 mmol, 60 mg) in one 
portion, and the mixture was stirred 2 more minutes, providing the diastereomeric material for 
radio-TLC. 
 
Table 1. 
RF values for enantiomers, ratio of the RF values, solvent and type of silica TLC plates 
Fluorohydrin 
Amino acid 
derivative 
TLC plate Solvent (v/v) RF1 RF2 RF2/RF1 
8-fluorocyclooct-4-enol 
Boc-Ala-
OSu 
regular 
40/60 
EtOAc/Hept 
0.60 0.66 1.10 
8-fluorocyclooct-4-enol 
Boc-Ala-
OSu 
chiral 
40/60 
EtOAc/Hept 
0.70 0.72 1.03 
8-fluorocyclooct-4-enol 
Boc-Ala-
OSu 
C18 
40/60 
EtOAc/Hept 
0.79 0.85 1.08 
8-fluorocyclooct-4-enol 
Boc-Ala-
OSu 
C18 
20/80 
EtOAc/Hept 
0.53 0.60 1.13 
8-fluorocyclooct-4-enol 
Boc-Phe-
OSu 
regular 
20/80 
EtOAc/Hept 
0.37 0.39 1.06 
8-fluorocyclooct-4-enol 
Boc-Phe-
OSu 
C18 
20/80 
EtOAc/Hept 
0.50 0.55 1.09 
2-fluorocyclohexanol 
Boc-Ala-
OSu 
C18 
10/1 
Tol/EtOAc 
0.569 0.639 1.12 
2-fluorocyclopentanol 
Boc-Ala-
OSu 
regular, C18 
and chiral 
10/1 
Tol/EtOAc 
no separation 
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2-fluorocyclopentanol 
Boc-Phe-
OSu 
2-fluorocyclopentanol 
Boc-Pro-
OSu 
C18 
5/1 
Tol/EtOAc 
0.52 0.55 1.07 
2-fluorocyclopentanol Boc-Ala-
OSu, 
Boc-Phe-
OSu 
regular, C18 
and chiral 
Tol/EtOAc, 
CHCl3/CH3CN 
no separation 
F-MISO 
F-MISO 
Boc-Val-
OSu 
C18 
1/1 
Tol/EtOAc 
0.41 0.46 1.12 
F-MISO 
Boc-Val-
OSu 
C18 
5/1 
Tol/EtOAc 
0.28 0.33 1.17 
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Table 2. Radiofluorination of meso-epoxides 
Fluorohydrin t, °C RCY, % ee, % Solvent 
2-fluorocyclopentanol 100 73 20 Tol/EtOAc 5/1 
2-fluorocyclohexanol 100 93 48 Tol/EtOAc 5/1 
8-fluorocyclooct-4-enol 100 78 33 Hept/EtOAc 4/1 
8-fluorocyclooct-4-enol 75 25 48 Hept/EtOAc 4/1 
8-fluorocyclooct-4-enol 50 5  Hept/EtOAc 4/1 
8-fluorocyclooct-4-enol 25 0  Hept/EtOAc 4/1 
 
 
 
[18F]8-fluorocyclooct-4-enol (1 h at 100 °C). C18-silica plate, Hept/EtOAc 4/1, RF=0.40  
78% RCY (average, 81% (max) 
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[18F]8-fluorocyclooct-4-enol, derivatized with Boc-Ala-OSu, C18-silica plate, Tol/EtOAc 5/1 
RF1=0.51, RF2=0.56 
33% ee (average, the Rfs were compared with the “cold” standard) 
 
 
 
[18F]2-fluorocyclohexanol. C18-silica plate, Tol/EtOAc 5/1 
RF=0.38 
93% RCY (average, max 93% ) 
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2-fluorocyclopentanol. C18-silica plate, Tol/EtOAc 5/1 
RF=0.36, 73% RCY (average, 75% max) 
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Table 3. 
RCY and ee for [18F]F-MISO at different temperatures 
t, °C RCY, % ee,% 
25 17  
50 81 55 
75 81 38 
100 87 33 
 
[18F]F-MISO, 97 % radiopurity 
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[18F]F-MISO, 1 h at 100 °C, regular silica 
87% RCY 
 
 [18F]F-MISO, 1 h at 75 °C, regular silica 
81% RCY 
 
 [18F]F-MISO, 1 h at 50 °C, regular silica 
81% RCY 
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Derivatized with Boc-Val-OSu, C18-silica plate, Tol/EtOAc 5/1 
55% ee 
 
 
[18F]F-MISO, 1 h at 25 °C, regular silica 
17% RCY 
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Radiotraces of (R) and (S)-[18F]F-MISO-Val-Boc 
(S)-[18F]F-MISO-Val-Boc 
RF=0.42, C18-silica plate, Tol/EtOAc 1/1 
 
 
(R)-[18F]F-MISO-Val-Boc 
RF=0.45, C18-silica plate, Tol/EtOAc 1/1 
 
 
 
 
  
0 50 100 150 mm
TLC
0
10
20
30
40
50
60
70
80
90 C/mm 
Or
ig
in
Re
g 
#1
Re
g 
#2
0 50 100 150 mm
TLC
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
C/mm 
Or
ig
in
Re
g 
#1
Re
g 
#2
 14 
 
Column: Chiralpak AD-3 (AD30CT-QK002) 
Flow Rate: 0.150 mL/min 
Isocratic conditions, 10% iPrOH in Hex 
 
[18F]2-fluorocyclohexanol  ee 45% (from 3 experiments) 
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[18F]2-fluorocyclopentanol ee 20% (from 3 experiments) 
 
  
 
[18F]8-fluorocyclooct-4-enol  ee 32% (from 3 experiments) 
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Column: Astec Chiraldex B-DM 40m x 0.25mm x 0.12um 
Linear velocity: 36 cm/sec 
Isotermalconditions (80 OC) 
 
2-fluorocyclopentanol, racemic
 
2-fluorocyclopentanol (“cold” experiment, 100 OC),  ee 52% 
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2-fluorocyclohexanol, racemic 
 
2-fluorocyclohexanol (“cold” experiment, 100 OC),  ee 24% 
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8-fluorocyclooct-4-enol, racemic 
 
8-fluorocyclooct-4-enol (“cold” experiment, 100 OC), ee 61% 
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“Cold”reaction mixture (100 °C, 10 min) before the purification procedure 
ee 40% (from 2 experiments) 
 
 
 
 
F-MISO (100 °C, 10 min) after the purification procedure 
ee 40% (from 2 experiments) 
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F-MISO (100 °C, 10 min) after the purification procedure  
ee 40% (from 2 experiments) 
 
 
 
 
F-MISO (racemic reference material) 
ee 0% 
 
  
 21 
 
MISO epoxide 
 
 
 
 
 
(-)-tetramisole 
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Column: Phenomenex Luna 3u C18(2) 100A, 100x2.00mm 
Flow Rate: 0.200 mL/min 
Isocratic conditions: 9/1 (5% ACN in H2O)/(100% ACN) 
10 min isocratic conditions – UV trace 
 
10 min isocratic conditions - radio HPLC trace 
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25 min isocratic conditions – UV trace 
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Column: Chiralpak AD-3 (AD30CT-QK002) 
Flow Rate: 0.150 mL/min 
Isocratic conditions, 10% iPrOH in Hex 
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radio trace, ee 44% 
 
 
UV-trace 
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radio trace, ee 44% 
 
 
UV-trace 
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The absolute stereochemistry of 8-fluorocyclooct-4-enol and 2-fluorocyclohexanol was assigned 
by NMR via derivatization of the fluorohydrins with the two enantiomers of α-methoxy-α-
trifluoromethylphenylacetyl chloride (MTPACl). 
The esters of these fluorohydines were prepared according to the described method7. 
 
A solution of DMAP (<0.1 mg, cat. amount), Et3N (6.1 μL, 0.0440 mmol, 10eq.) and fluorohydrin 
(0.0044 mmol, 1 eq.) in 0.5 mL of dry CH2Cl2 was prepared under argon and transferred into the 
NMR tubes. (S)-MTPACl (1.64 μL, 0.0088 mmol, 2 eq.) was added.  After 15 min the solvent was 
removed in vacuo, CDCl3 (0.6 ml) was added and the ampule was sealed under vacuo, providing 
a sample for NMR studies. The second sample with (R)-MTPACl was prepared similarly. 
Table 4. 
Fluorohydrin Proton ΔδSR 
Carbon 
configuration 
2-fluorocyclohexanol 
-FCH- 4.48-4.39=0.09 (pos.) 
S 
-CH2-HCO- 1.34-1.48= - 0.14 (neg.) 
8-fluorocyclooct-4-
enol 
-FCH- 4.78-4.70=0.08 (pos.) 
S 
-CH2-HCO- 
2.10-2.17= - 0.07 (neg.) 
1.72-1.86= - 0.14 (neg.) 
  
  
                                                     
7
 M. Seco, E. Quin, R. Riguera, Tetrahedron: Asymmetry 2002, 12, 2915–2925. 
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Column: Phenomenex Luna 3u C18(2) 100A, 100x2.00mm 
Flow Rate: 0.200 mL/min 
Isocratic conditions 1:1 (5% ACN in H2O):(100% ACN) 
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Enantiomerically enriched, from (R,R) Co(Salen), 19F 
 
ee 64% 
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Enantiomerically enriched, obtained from the reaction with (R,R) Co(Salen), ee 40% 
 
 
ee 38% 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Feci quod potui, faciant meliora potentes 
 
